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Hypoglycaemia is a very common side-effect of insulin therapy for diabetes and directly 
affects cognitive function.  It can be identified by the onset of symptoms and by blood 
glucose monitoring.  Impaired awareness of hypoglycaemia is an acquired syndrome in 
people with insulin-treated diabetes.  The definitions, frequency, causes, treatment and 
prevention of clinical hypoglycaemia and the effects on, and moderators of, cognitive 
function will be discussed.   
 Two studies have examined the effects of hypoglycaemia on tests of particular cognitive 
domains in subjects with and without type 1 diabetes. Three further studies have 
examined the frequency of hypoglycaemia in people with and without impaired 
awareness, the prevalence of impaired awareness of hypoglycaemia (IAH) and have 
compared methods of assessing awareness of hypoglycaemia.  
In study 1 the effect of acute hypoglycaemia on psychomotor function was examined in 
healthy volunteers (n =20) and adults with type 1 diabetes (n=16). Although acute 
hypoglycaemia caused significant impairment of several psychomotor functions in non-
diabetic adults, a lower magnitude of impairment was observed in those with type 1 
diabetes. The potential mechanisms behind this are discussed. 
In study 2 the effect of acute hypoglycaemia on a simple two-choice reaction time test, 
which has a model with validated performance parameters, was examined in 14 non-
diabetic volunteers. Application of the validated model to the results of this task 
revealed that hypoglycaemia affected central processing and was not related to the 
amount of evidence required to make a decision or to peripheral and motor processes. 
This study is the first to use this method to dissect the effects of hypoglycaemia on 
cognition and enhances understanding of the mechanism underlying neuroglycopenia in 
adults. 
In Study 3 the methods of evaluating awareness of hypoglycaemia were compared in 
people with type 1 diabetes. Good concordance in clinical characteristics and frequency 
of biochemical hypoglycaemia was observed between the methods described by Gold et 
al and Clarke et al but not with a Danish method.  
In study 4 continuous glucose monitoring (CGM) and home blood glucose monitoring 
were performed prospectively for 12 months in people with and without IAH. Those 
with IAH had a 1.6-fold higher incidence of biochemical hypoglycaemia as 
demonstrated by blood glucose monitoring, but CGM did not identify patients with 
IAH.  
In study 5 the prevalence of IAH in a large clinic population with type 1 diabetes was 
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Hypoglycaemia remains a common and feared side effect of treatment with insulin [1,2]. 
In addition to affecting most people with insulin-treated diabetes, it is also associated 
with sulphonylurea therapy in people with type 2 diabetes, but occurs much less 
frequently [3].   
In people without diabetes physiological insulin secretion is minimal in the fasting state, 
however once the blood glucose concentration starts to rise, insulin concentrations 
increase almost ten-fold within three to five minutes of the glucose rising.  Over time 
this lowers blood glucose concentrations and insulin secretion returns to basal levels. 
For people with insulin-treated diabetes treatment should ideally aim to provide a 
method of insulin delivery that replicates normal physiology. Despite improvements in 
insulin therapies, intensification of insulin regimens and innovative patient education the 
current methods of insulin replacement therapy for people with diabetes are far from 
physiological and marked variations occurring in intra- and inter-individual absorption 
of insulin. Thus hypoglycaemia remains almost an inevitable consequence of insulin 
therapy. 
Hypoglycaemia per se generates a range of unpleasant and uncomfortable symptoms that 
requires the person with diabetes to treat themselves to correct the condition.  If 
untreated or if the symptoms have been lost, it can lead to confusion or collapse, 
creating a significant risk of morbidity and mortality. Given this, in people with insulin-
treated diabetes, it is not surprising that fear of hypoglycaemia can lead to barriers in 
attaining good glycaemic control [2]. 
Good glycaemic control however is necessary to prevent diabetes-related complications. 





[4] and its follow up study the Epidemiology of Diabetes Intervention and 
Complications (EDIC) [5] trial have demonstrated that intensive treatment to achieve 
glycaemic control to as near the non-diabetic range as possible, results in fewer and less 
severe microvascular and macrovascular complications. In people with type 2 diabetes 
the benefits of strict glycaemic control on the prevention of microvascular 
complications was demonstrated in the UK Prospective Diabetes Study (UKPDS) [6]. 
Hence, if it was not for hypoglycaemia everyone with diabetes potentially could be 
complication free as the insulin dosage would simply be increased until blood glucose 
concentrations were within the non-diabetic range. However as the DCCT reported the 
risk of severe hypoglycaemia increases three-fold as glycaemic control is driven towards 
the non-diabetic range [7]. Improvements in insulin therapy, methods of administration 
and patient education have been made since the DCCT trial was conducted (1982-1993), 
yet hypoglycaemia remains a common side-effect of treatment especially in those with 
type 1 diabetes and it effects deserve to be researched further. 
 
 
1.2   Defining Hypoglycaemia 
 
Any attempts to quantify the frequency of hypoglycaemia require a precise criterion to 
diagnose an episode of hypoglycaemia. If Whipples triad [8] - symptoms compatible 
with hypoglycaemia, a low plasma or blood glucose concentration and resolution of 
symptoms after glucose concentrations are returned to normal, is considered to be the 
‘gold standard’ for diagnosing hypoglycaemia then this raises difficulties when this 
criteria is applied to people with type 1 diabetes.  
Symptoms of hypoglycaemia are idiosyncratic and age specific and are affected by 





insulin therapy with many people with type 1 diabetes experiencing a reduction in 
symptom intensity or a change in symptom profile with time [2,9-11]. Neuroglycopenic 
symptoms such as confusion, drowsiness and an inability to concentrate become 
predominant, while autonomic symptoms such as tremor, sweating, palpitations etc 
diminish in prevalence and intensity (Figure 1.1). This leads to the development of  
“impaired awareness of hypoglycaemia”, which is recognised to be an acquired 
syndrome associated with cerebral adaptation resulting from recurrent exposure to low 
blood glucose levels [9]. Hence many episodes of hypoglycaemia can be unrecognised or 
asymptomatic. In a prospective study of 411 people with type 1 diabetes (65% of whom 
classified themselves as having normal awareness of hypoglycaemia) Pramming and 
colleagues reported that when patients had symptoms suggestive of hypoglycaemia only 
29% of such episodes were accompanied by evidence of biochemical hypoglycaemia  (< 
3.0 mmol/L) [2]. Thus solely relying on symptoms appears to be a relatively insensitive 














Figure 1.1: Changes in symptoms of hypoglycaemia with increasing duration of 



























The biochemical definition of hypoglycaemia seems to raise just as many problems as 
attempts to define hypoglycaemia by symptomatic responses as described above. 
Hypoglycaemia provokes a hierarchy of events that occur at individual glycaemic 
thresholds, commencing with counterregulation (arterialised venous blood at ~ 3.6-3.9 
mmol/L), onset of symptoms (~ 3.0-2.8 mmol/L) and cognitive dysfunction (~ 2.8-2.4 
mmol/L). These glycaemic thresholds are reproducible in non-diabetic individuals 
[12,13]  (Figure 1.2), but are dynamic in people with diabetes and can be altered by 
external factors such as glycaemic control or recent preceding (antecedent) 
hypoglycaemia. Patient with poor preceding control may experience symptoms of 
hypoglycaemia at venous plasma glucose concentrations substantially in excess of 3.0 
mmol/L [14]. Whilst patients with strict preceding control may not experience 
symptoms until venous plasma concentrations have fallen below 2.0 mmol/L [15] 
In routine clinical practice low blood glucose concentrations that require treatment 
should be set on an individual basis however, a generic lower blood glucose 
concentration of  <4.0 mmol/L has been advised by both the American Diabetes 
Association and Diabetes UK [16,17] . 
Finally, the type of blood in which glucose is measured needs to be considered. In 
routine clinical practice it is the norm for venous blood glucose concentrations to be 
measured. Arterial blood then ultimately capillary blood supplies glucose to tissues 
hence arterial plasma glucose concentration is the most accurate assessment of the 
actual blood glucose concentration. However as arterial sampling is invasive and can be 
painful venous concentrations are more often used in clinical practice, although these 






Figure 1.2: Hierarchy of endocrine, symptomatic and neurophysiological 
responses to acute hypoglycaemia in non-diabetic subjects.  Adapted from 
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1.2.2  Definition of severity of hypoglycaemia 
 
The American Diabetes Association Workgroup on Hypoglycaemia [17] has classified 
hypoglycaemic episodes as: 
• Severe hypoglycaemia - an event requiring assistance of another person to 
actively administer carbohydrate, glucagon or other resuscitative actions. 
• Documented symptomatic hypoglycaemia – an event during which typical 
symptoms of hypoglycaemia are accompanied by a measured plasma glucose 
concentration < 3.9 mmol/L. 
• Asymptomatic hypoglycaemia – an event not accompanied by typical symptoms 
of hypoglycaemia but with a measured plasma glucose concentration of < 3.9 
mmol/L. 
• Probable symptomatic hypoglycaemia – an event during which symptoms of 
hypoglycaemia are not accompanied by a plasma glucose determination (but that 
was presumably caused by a plasma glucose concentration of < 3.9 mmol/L. 
• Relative hypoglycaemia – an event during which the person with diabetes 
reports any of the typical symptoms of hypoglycaemia, and interprets those as 
indicative of hypoglycaemia, but with a measure plasma glucose concentration 
of > 3.9 mmol/L. 
 
However in general terms most episodes are classified as mild if they can be self-treated 







1.2.3 Conclusions regarding hypoglycaemia definition 
 
Given the inherent limitations of relying on symptoms only to diagnose hypoglycaemia 
and the difficulties surrounding choosing an appropriate plasma glucose for which to 
define hypoglycaemia in people with type 1 diabetes not surprisingly there is no current 
consensus on how it should be defined.  In an ideal world patients would perform home 
blood glucose monitoring to document a glucose concentration < 4.0 mmol/L when 
they perceive themselves to be hypoglycaemic then treat this appropriately. In reality 
this rarely happens and patients simply self-treat which ultimately is the safest mode of 
action.  
Many have argued that the plasma glucose concentration of < 4.0 mmol/L as suggested 
by Diabetes UK and the ADA [16,17] to define hypoglycaemia is too high given the fact 
that at this level it would have no effect on symptom generation, hormonal responses or 
affect cognitive function and have suggested that a concentration of 3.5mmol/l to 
define the onset of hypoglycaemia would be more clinically relevant [19].  
 
1.3 Frequency of hypoglycaemia  
 
The frequency of hypoglycaemia in people with type 1 diabetes is difficult to estimate 
accurately. Recall of mild hypoglycaemia, unlike severe hypoglycaemia which has been 
shown to be robust for upto year after the event [20], is generally unreliable after one 
week [2]. Therefore to accurately document the frequency of hypoglycaemia this should 





Current available methods for assessing this frequency include home blood glucose 
monitoring (HBGM) and continuous glucose monitoring (CGMS). Home blood glucose 
monitoring has its limitations in that the frequency of hypoglycaemia is dependent on 
the frequency and timing of testing. Thus it is likely that even if the person with type 1 
diabetes is checking the recommended four times a day, any inter-prandial, and in 
particular nocturnal, hypoglycaemic event may be missed and may therefore cause 
underestimation of the true frequency. Therefore the introduction of CGM whereby an 
interstitial glucose value is measured every 3 minutes for a period of up to 72 hours 
would appear to circumvent these problems and be the “gold standard” for estimating 
hypoglycaemia frequency in people with type 1 diabetes. Concerns however have been 
expressed about the accuracy of CGM, particularly at hypoglycaemic levels [21] because 
of the physiological delay between blood and interstitial glucose which may be 
exaggerated when blood glucose is falling rapidly [22]. In patients with type 1 diabetes 
during experimental hypoglycaemia, CGM has been proven to underestimate interstitial 
tissue glucose concentrations [23] and potentially overestimate the frequency of 
hypoglycaemia. 
 
1.3.1 Frequency of mild hypoglycaemia 
 
Comparing studies of hypoglycaemia frequency is problematic due to variations in study 
design, heterogeneity of populations and differing definitions of hypoglycaemia 
confounding comparisons. The studies that have examined this frequency have reported 
widely varying rates of hypoglycaemia at between 8 to 160 episodes per patient per year 








Pedersen-Bjergard and colleagues in two large retrospective studies (2001 & 2004) of 
201 and 1076 patients respectively, documented patient recall of mild, symptomatic 
hypoglycaemia, during the preceding week, at two episodes per week [24,25]. Both 
studies included a high percentage of participants on intensive insulin regimens and had 




Prospectively collected data on the frequency of hypoglycaemia should theoretically 
provide more accurate data but again the reported rates vary widely. Pramming and 
colleagues in a study preformed in 1990 (which confirmed the validity of patient recall 
of mild hypoglycaemia for up to one week) of 411 people with type 1 diabetes, reported 
an average of 1.8 episodes of mild symptomatic hypoglycaemia per week [2]. Limitations 
of this earlier study are that 78% of participants were managed on twice-daily soluble 
and isophane insulin’s thus making it less relevant today due to the widespread use of 
intensive insulin regimens and insulin analogues. 
Pedersen-Bjergard and colleagues also examined the frequency of mild hypoglycaemia 
prospectively in 2003 [26]. Questionnaires were sent monthly for 12 months to 
participants in order for them to record all episodes of mild symptomatic 
hypoglycaemia. This occurred on average 1.7 times per patient per week. The results of 
the studies reported by Pederson-Bjergard and the earlier study of Pramming and 
colleagues have to be interpreted with a degree of caution. All of these studies reported 
a high percentage (up to 50%) of participants with impaired awareness of 





hypoglycaemia will therefore over estimate the true frequency. Questions however have 
been raised about the validity of the Danish method of assessing awareness of 
hypoglycaemia and will be discussed in Chapter 7.  
In a prospective study from Dundee, Donnelly and colleagues examined the frequency 
of mild symptomatic hypoglycaemia in 94 people with type 1 diabetes (49% male, 
median age 40 years with a median duration of diabetes 18.1 years) [27]. Rates of mild 
symptomatic hypoglycaemia was reported as 42.89 episodes per patient per year. This 
reported rate is roughly half the rate reported by Pramming and Pedersen-Bjergard et al 
which maybe due to the atypical groups recruited in the Danish studies as discussed 
above. The study from Dundee also has some limitations: namely the criteria for 
defining hypoglycaemia was not described and there appeared to be no standard set for 
the frequency of HBGM as “patients were not required to deviate from their normal 
routine of blood glucose monitoring”, which is ultimately going to affect the reported 
frequency. 
In a study from our centre which examined the frequency and severity of hypoglycaemia 
in the workplace, 243 adults were examined prospectively over a 12 month period [28]. 
This study reported a frequency of mild symptomatic hypoglycaemia of only eight 
episodes per patient per year, significantly below that previously reported for people 
with type 1 diabetes. The group of people studied was atypical from the normal clinic 
population for several reasons.   The study reported a very low prevalence of impaired 
awareness of hypoglycaemia at only 3% in the group of 243 people with insulin-treated 
diabetes who were in full-time employment. The participants themselves were mainly 
‘white collar’ workers in management and professionals with few people undertaking 





of people with insulin treated type 2 diabetes were also included (11%). Thus all of the 
above namely the low percentage of participants with impaired awareness, the poor 
glycaemic control and the small number of subjects with type 2 diabetes could have 
lowered the frequency of hypoglycaemia. 
The UK Hypoglycaemia Study group consisted of six secondary care centres (of which 
Edinburgh was one) and examined the frequency of hypoglycaemia in type 1 and type 2 
diabetes [29]. In total 107 subjects with type 1 diabetes were recruited. Their baseline 
demographics are below in Table 1.1. All participants were provided with similar 
capillary glucose testing devices (Medisense G glucose meter, Abbott Laboratories, 
Abbott Park, IL, USA) and were requested to perform one four-point blood glucose 
profile daily, (three measurements before meals and one at bedtime) in a 24 hour period, 
once a week for the duration of the study (12 months). Participants were contacted 
monthly by members of the research team to collect both the BGM and self-reported 
hypoglycaemia data. This group reported a frequency of mild hypoglycaemia in those 
with type 1 diabetes < 5 years of 35.5 episodes per patient per year. In those with 
duration > 15 years rather surprisingly the reported rate was lower at 29.0 episodes per 
patient per year. If we exclude the study by Leckie and colleagues (due to the difficulties 
of transferring data obtained from an atypical group recruited specifically for a study 
examining hypoglycaemia in the workplace) then this study has the lowest reported rate 
of mild hypoglycaemia. This study had numerous strengths: a prolonged follow-up 
period and was conducted at multiple centres throughout the United Kingdom. 
However this prolonged follow up may have lead to ‘patient fatigue’ with patients 






Table 1.1: Baseline characteristics of the participants with type 1 diabetes in the 
UK Hypoglycaemia Study,  [29]. 
 Type 1 < 5 years, n= 50 Type 1 > 5 years, n= 57 
Sex (% male) 70.0 57.9 
Age (years) 41.3 (12.7) 53.2 (10.4) 
BMI (kg/m2) 26.1 (4.3) 27.9 (4.9) 
Duration of diabetes (years) 3.0 (1.3-3.8) 29.8 (21.5-40.3) 
Baseline HbA1c 7.3 (1.02) 7.8 (0.73) 
1 year HbA1c 7.3 (1.16) 7.6 (0.85) 
Fasting C pep (nmol/l) 0.37 (0.17-0.58) 0.09 (0.05-0.26) 
Post-glucagon C peptide 
(nmol/l) 
0.45 (0.25-0.69) 0.09 (0.05-0.26) 

















1.3.2 Frequency of severe hypoglycaemia 
 
 
The frequency of severe hypoglycaemia reported in studies is more consistent than that 
of mild hypoglycaemia presumably due to the profound effect that each episodes has on 
the patient, thus providing a more robust end point. Recall of such events have been 
demonstrated to be robust for up to a period of one year [20].     
In population surveys, estimates of the incidence of severe hypoglycaemia in type 1 
diabetes range from 1.0 to 1.7 episodes per person per year, with annual prevalences of 
30 to 40% [25,30-32].  Table 2 describes the larger studies that have examined this, out 
with clinical trials in unselected groups of individuals with type 1 diabetes. Intervention 
trials such as the Diabetes Control and Complications Trial reported lower frequencies 
of severe hypoglycaemia at 0.19 (conventional treatment group) and 0.62 (intensive) 
episodes per year, which must be at least partly due to the highly motivated patient 
group of young, healthy individuals of above average intelligence, who had type 1 
diabetes of short duration [7].  Patients with two or more episodes of severe 
hypoglycaemia in the preceding two years were also excluded from the DCCT based on 
the feasibility study of 278 participants.  Participants in the intensive cohort were also 
seen on a monthly basis by a diabetes doctor, nurse, dietician and psychologist, which 
would not be feasible in normal clinical practice. 
Severe hypoglycaemia can lead to total amnesia and hence as only one in ten of all 
episodes of severe hypoglycaemia result in contact with the emergency services, as 
demonstrated by Leese and colleagues in Dundee [33], verification of these episodes 





Table 1.2: Data from studies examining the frequency of severe hypoglycaemia (requiring third party assistance) in adults with type 
1 diabetes.  
 
Study Participants Type of study Follow up HbA1c Frequency 
(per/pt/yr) 
Pramming et al 1991 411 Prospective 1 week 8.7 1.4 
MacLeod et al 1993 600 (56 with 
T2DM) 
Retrospective 12 months 10.7 (A1) 1.6 
Mulhauser et al 1998 684 Retrospective 12 months 8.0 0.21 
Ter Braack et al 
2000 
195 Retrospective 12 months 7.8 1.5 
Pedersen-Bjergaard 
et al 2001 
207 Retrospective 24 months 8.6 1.1 
Pedersen-Bjergaard 
et al 2003 
170 Prospective 12 months 8.4 1.1 
Pedersen-Bjergaard 
et al 2004 
1076 Retrospective 12 months 8.6 1.3 
Leckie et al 2005 243 (27 with 
T2DM) 
Prospective 12 months 9.1 0.98 
UK  Hypo Group 
2007 




1.4 Causes of hypoglycaemia  
 
Causation of hypoglycaemia is often multi-factorial and no definite cause can be 
identified in many episodes. Common causes are discussed below. 
 
Patient errors:  On a daily basis a person with Type 1 diabetes has negotiate their blood 
glucose in order to avoid hyper and hypoglycaemia. Inaccurate calculation of the 
amount of insulin required for a meal, delayed or even missed meals can lead to 
hypoglycaemia. This is exacerbated not only by the content of the meals affecting the 
absorption rate [34,35] but also the intra-individual variability in insulin absorption [36] .  
 
Exercise: In non-diabetic humans moderate exercise results in a 40-50% reduction in 
circulating concentrations of insulin, below pre-exercise levels [37]. In people with type 
1 diabetes exercise either needs to be accompanied by a reduction in exogenous insulin 
prior to exercise or an increase in the consumption of carbohydrate. The absorption of 
insulin is accelerated if exercise commences shortly after the insulin injection 
(particularly when the insulin has been injected into an exercised limb, such as the leg), 
and enhances the risk of hypoglycaemia.  An acute increase in insulin sensitivity also 
occurs post exercise increasing the risk of delayed hypoglycaemia [38] . 
 
Renal Failure: Insulin requirements are lower in people with advancing renal failure.  As 
their metabolic clearance of insulin is reduced an increased insulin activity is observed.  
People with renal impairment (raised serum creatinine) have a five-fold higher incidence 
of severe hypoglycaemia compared to matched subjects with normal kidney (creatinine) 





Co-existent endocrine disease: Endocrine disorders that result in cortisol deficiency, such as 
Addison’s disease and hypopituitarism, due to a decrease in the concentration of 
counterregulatory hormones, are associated with a higher frequency of hypoglycaemia. 
 
Malabsorption and gastroparesis: Conditions, such as Coeliac Disease (which more common 
in people with type 1 diabetes) can generate nil, non-specific or mild symptoms making 
it a potentially difficult diagnosis to make. If however a patient with Type 1 diabetes has 
unexplained episodes of hypoglycaemia, Coeliac serology should be performed 
especially if the patient is losing weight. Autonomic neuropathy can result in delayed 
gastric emptying or frank gastroparesis thus affecting the balance of  carbohydrate and 
insulin absorption promoting hypoglycaemia[40] . 
 
Factitious hypoglycaemia: Insulin is a powerful tool in order to manipulate blood glucose 
concentrations. Deliberate induction of hypoglycaemia appears to be rare and can be 
often difficult to detect or confirm.  It should be suspected if repeated severe 
hypoglycaemia occurs with no obvious cause.   
 
Drugs and toxins:  Alcohol suppresses hepatic glucose output, increasing the risk of 
nocturnal hypoglycaemia.  Alcohol also impairs the awareness of hypoglycaemia and 
hinders the individual’s ability to take corrective action and prevent progression of mild 
to severe hypoglycaemia. Up to 19% of all episodes of severe hypoglycaemia 
necessitating hospital admission have implicated alcohol ingestion [41]. Some drugs, 
including ACE inhibitors and disopyramide, also have been linked to increased insulin 





1.5 Risk Factors for Severe Hypoglycaemia 
 
Episodes of severe hypoglycaemia can result in accidents, coma, and even death. Not 
surprisingly it discourages patients and health care providers from pursuing intensive 
glucose control.  The DCCT concluded that only about 8% of future severe 
hypoglycaemic episodes could be predicted from known variables [7], and a recent 
structural equation model accounted for 18% of the variance in SH using history of SH, 
hypoglycaemia awareness, and autonomic symptom score [44]. Therefore current 
researchers have been looking past traditional risk factors in an attempt to try and 
predict those at risk of severe hypoglycaemia, and those along with the role of 
traditional risk factors will be discussed below. 
 
Intensive insulin therapy 
 
The Diabetes Control and Complications Trial Research Group demonstrated that strict 
glycaemic control decreased the incidence of microvascular complications in people 
with type 1 diabetes [4]. One thousand four hundred and forty one people with type 1 
diabetes were randomised to either intensive insulin therapy (with multiple daily insulin 
injections or pumps, frequent blood glucose monitoring, monthly visits and frequent 
telephone advice) or conventional insulin therapy (one to two injections per day, 
infrequent blood glucose monitoring and three monthly visits. After a follow-up period 
of approximately 6.5 years the mean HbA1c in the intensive group was 7.0% compared 
to 8.8% in the conventional group. The incidence of severe hypoglycaemia in the 
intensive group was three times that compared to the conventional group (0.62 versus 
0.19 episodes per patient per year [7]. Similar results were seen in the Stockholm 





intensive or conventional treatment groups [45]. Rates of severe hypoglycaemia were 
again almost three-fold higher in the intensive group (1.1 versus 0.4 episodes per patient 
per year). Other studies have managed to improve glycaemic control but not increase 
the risk of severe hypoglycaemia via structured in-patient education programmes prior 
to intensification of insulin therapy. 
 
Previous severe hypoglycaemia 
The main risk factor for severe hypoglycaemia in the DCCT was a history of previous 




In people with type 1 diabetes, the relative insulin excess from exogenous insulin leads 
to a fall in glucose concentrations. As the glucose concentrations fall, the plasma insulin 
levels cannot decrease as observed in people without diabetes. Thus the first line of 
defence against hypoglycaemia is lost. With falling glucose concentrations the 
concentration of glucagon should also increase but this response is diminished early in 
the course of type 1 diabetes, and within a few years becomes negligible or non-existent.  
Patients who do not mount a glucagon response to hypoglycaemia can secrete glucagon 
in response to arginine infusion [46]. This paradox appears to have been explained 
recently by the ‘intra-islet hypothesis’, which postulates that glucagon release in response 
to hypoglycaemia also requires a fall in intra-islet insulin concentration, and hence a 
reduction in tonic α-cell inhibition [47].  In type 1 diabetes, intra-islet insulin 
concentrations are close to zero at all times due to endogenous insulin deficiency and no 
such fall is possible.  Therefore the third line of defence, the epinephrine response 





attenuated with antecedent hypoglycaemia shifting the thresholds to a lower level [48-
50]. The loss of all three lines of defence against hypoglycaemia substantially increases 
the risk of hypoglycaemia. 
 
 
Impaired awareness of hypoglycaemia 
 
With increasing duration of treatment with insulin many people with type 1 diabetes 
experience a change in their symptoms of hypoglycaemia [2, 9-11], manifested as either a 
reduction in intensity or number, or a change in symptom profile, so that 
neuroglycopenic symptoms predominate, while autonomic symptoms are less 
prominent or absent. This diminished ability to perceive the onset of hypoglycaemia 
(impaired awareness of hypoglycaemia (IAH), is alleged to affect approximately 20-25% 
of people with type 1 diabetes [51-53].  Studies in people with impaired awareness have 
documented a 3-6 fold increase in the risk of severe hypoglycaemia compared to those 
with intact awareness [51-53]. 
 
Hypoglycaemia –Associated Autonomic Failure 
Hypoglycaemia Associated Autonomic Failure (HAAF) has been postulated to occur in 
both type 1 diabetes and advanced insulin-treated type 2 diabetes, the concept being that 
recurrent hypoglycaemia results in a failure of the centrally-mediated sympatho-adrenal 
response which promotes counterregulatory failure and impaired awareness of 
hypoglycaemia (Figure 1.3), [47].   
 
Low blood glucose index 
 
The low blood glucose index (LBGI) is a measure of the frequency and extent of low 





specific distribution of blood glucose data [54-56] as in people type 1 diabetes as it is 
substantially asymmetric, with the hypoglycaemic range (<3.9 mmol/L) numerically 
much smaller than the hyperglycaemic range (>10 mmol/L). As a result, standard 
statistics, such as the mean and SD, tend to underestimate patients’ risk for 
hypoglycaemia. The LBGI is a non-negative quantity that increases when the number 
and/or the absolute extent of low blood glucose readings increase. The LBGI is also not 
influenced by hyperglycaemia (all readings above 6.25 mmol/L have zero loads) unlike 
the mean and SD. Thus LBGI has been proven to predict severe hypoglycaemia better 
than any other standard statistic with the LBGI accounting for between 40-48% 




















Figure 1.3: Diagrammatic representation of the concept of hypoglycaemia-
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Serum angiotensin-converting enzyme (ACE) activity has emerged as a possible marker 
for risk assessment.  Individual variation in serum ACE levels is mediated in part by 
gene polymorphism, via I (insertion) and D (deletion) alleles.  The II genotype is 
associated with low serum ACE activity [58] and in type 1 diabetes has been linked to a 
low frequency and risk of severe hypoglycaemia; the DD genotype is associated with 
higher serum ACE activity which has been suggested to be an index of an increased risk 
of SH [23,25].  Low serum ACE and the II genotype are associated with enhanced 
athletic performance in events requiring stamina, and have a higher than normal 
prevalence in high altitude mountaineers [59-61].  A hypothetical explanation for these 
findings is that a lower ACE activity confers greater ability to function efficiently during 
periods of metabolic substrate deprivation.  Conversely, those who have a high ACE 
activity have more limited functional capacity when challenged by glucose deficiency.   
In people with type 1 diabetes with high ACE activity, this may be manifest by greater 
cognitive impairment during hypoglycaemia than in those with low ACE activity.  This 
difference in the capability of the brain to function during glucose deprivation, might 
explain the variable risk of developing severe hypoglycaemia within a population with 
type 1 diabetes.  Two Danish studies in adults, and one Swedish study in children and 
adolescents, all with type 1 diabetes, have demonstrated that a high serum ACE activity 
is associated with an increased risk of SH [24,26,62]. However a study from our own 
centre in Edinburgh of 300 adults with type 1 diabetes failed to demonstrate a 
convincing association between ACE concentrations and severe hypoglycaemia (Figure 








Figure 1.4:  The relationship between number of episodes of severe 
hypoglycaemia (SH) experienced by individual participants during the previous 
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1.6 Treatment of hypoglycaemia 
 
 
Mild hypoglycaemia is usually self-treated with oral carbohydrate.  Guidelines exist for 
the self-treatment of mild symptomatic hypoglycaemia, and suggest the initial 
consumption of roughly 20 grams of fast-acting carbohydrate, preferably as glucose (e.g. 
3 dextrose tablets) followed by longer-acting carbohydrate in the form of starch 
(banana, cereal or biscuits). A glucose gel preparation can be applied to the buccal 
mucosa (although jam and honey work equally well) if the patients conscious level is 
high enough, due to the risk of aspiration with a decreased level of consciousness.  All 
forms of refined sugar take on average 15 minutes to relieve symptoms. While the 
symptoms are persisting during this period many patients over-treat their hypo leading 
to rebound hyperglycaemia. Unconscious patients should receive 50% dextrose as an 
intravenous bolus of 20-50 ml (although this concentration may provoke 
thrombophlebitis and many advocate a larger bolus of 10-20% Dextrose) and, if 
hypoglycaemia is protracted, an intravenous infusion of 10-20% dextrose may be 
required to maintain euglycaemia.  Intramuscular or intravenous glucagon may also be 
given to stimulate conversion of glycogen into glucose, but if the hypoglycaemia has 
been precipitated by, or is associated with, excessive alcohol intake, glucagon may be 
ineffective as alcohol blocks the glycogenolytic action of glucagon to convert hepatic 
glycogen into glucose.  If the patient has a prolonged episode of hypoglycaemia 
glucagon will also be ineffective as hepatic glycogen will have been exhausted. Therefore 








1.7  Prevention of hypoglycaemia 
 
Education of people with diabetes must include advice on not only how to recognise 
and treat hypoglycaemia but also on how to prevent it. Current strategies are discussed 
below. 
 
Insulin analogues and alternative regimens 
Short-acting insulin analogues, which have a rapid onset and short duration of action, 
are effective in reducing the incidence of hypoglycaemia in people with type 1 diabetes 
[64].  They are of particular benefit in people with unpredictable lifestyles, as they allow 
greater flexibility in timing and dosage of insulin and timing of meals.  The long-acting 
insulin analogue, insulin glargine, has been shown in some studies to be beneficial in 
reducing the incidence of hypoglycaemia, particularly at night [64].   
The National Institute of Clinical Excellence recent technology appraisal guidance on 
the use of Continuous Subcutaneous Insulin Infusion (CSII) for diabetes recommends 
that CSII be reserved for people with Type 1 diabetes when other therapy has been 
unable to maintain glycated haemoglobin levels <7.5% without disabling hypoglycaemia 
[65]. Previous research has demonstrated a dramatic reduction in episodes of severe 
hypoglycaemia in patients transferring from a basal bolus regimen with human insulin’s 
to CS11 [66]. 
 
Diabetes education 
Dose Adjustment for Normal Eating courses (DAFNE) are outpatient-based 





intensive insulin treatment. Participants are taught to match insulin doses to their food 
choices, while keeping their blood glucose close to normal, hopefully with minimal 
input from clinicians once they have completed the course. The initial DAFNE trial 
demonstrated a sustained improvement in glycaemic control at one year without 
increasing the risk of severe hypoglycaemia [67]. 
 
Home blood glucose monitoring 
No clear evidence exists to show that frequent home blood glucose monitoring can 
reduce the occurrence of severe hypoglycaemia. The Low Blood Glucose Index 
however has been demonstrated to predict imminent (i.e. within 24 hours episodes) of 
58-60% of episodes of severe hypoglycaemia using only three values from home blood 
glucose monitoring [68]. With more readings available the accuracy appears to increase. 
Unfortunately at present this mathematical equation is not routinely available, although 
hopefully this can be incorporated into a metered device at some stage. Despite the lack 
of evidence for HBGM it appears logical to continue to encourage people with insulin 
treated type 1 and 2 diabetes to continue to check their blood glucose on regular 
occasions to detect asymptomatic episodes of hypoglycaemia and facilitate adjustments 
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2.1 Methodical Considerations 
 
 
Reproducible studies examining the effects of hypoglycaemia on cognitive function did 
not become feasible till the late 1970’s and throughout the 1980s, although the effects of 
hypoglycaemia on cognitive function were first reported in the 1920s after insulin was 
discovered [1]. A considerable volume of literature has accumulated on these effects and 
will be discussed in detail later. Prior to this however, the methodical differences and 
limitations of procedures employed in the studies will be examined. 
 
Method of induction of hypoglycaemia   
Two main techniques have been used to induce hypoglycaemia in the experimental 
setting. The insulin infusion technique involves an intravenous infusion of insulin, at a 
variable rate, to achieve the desired blood glucose concentration. The hyperinsulinaemic 
glucose clamp technique involves infusing a constant high dose of insulin, to saturate 
insulin receptors and deliver a maximal hypoglycaemic response, while varying the 
amount of dextrose infused [2].  The hyperinsulinaemic clamp technique has gained 
widespread popularity over the past 30 years due to the fact that rapid changes in blood 
glucose concentrations can be made. Both techniques however have disadvantages. The 
concentrations of insulin infused vary widely between the two techniques with the 
clamp technique employing supra-physiological doses and the insulin infusion technique 
employing variable insulin concentrations.  
The human brain is almost entirely dependant on glucose for its energy [3], with a 
minimal contribution from ketone bodies, amino acids and lactate during the acute state 
[4]. Transport of glucose into the brain is mediated via glucose transporters (GLUT 1 to 





been demonstrated throughout the human brain with particularly high concentrations in 
the hypothalamus, cerebellum and cortex [5]. Pardridge and colleagues have also 
demonstrated the presence of insulin receptors at the blood brain barrier [6]. Glucose 
transporters such as the insulin sensitive GLUT 4 transporters and partially insulin 
sensitive GLUT 1 transporters have been observed at the blood brain barrier brain and 
on glial cells in various animal studies [7-11]. Therefore, it would appear that the supra-
physiological doses of insulin used in the hyperinsulinaemic glucose clamp procedure 
could potentially improve transport of glucose across the blood brain barrier and thus 
protect against neuroglycopenia improving cognitive function. Most studies in both 
humans and animals do not however appear to show an effect of increasing circulating 
insulin concentrations above that, which is normally found in the fasting state, on 
glucose transport across the blood brain barrier [12-14]. In a recent study Bingham and 
colleagues demonstrated that unlike the above research brain glucose uptake is partially 
insulin sensitive as when insulin is infused at a sub-physiological dose a reduction in 
brain glucose metabolism was observed [15] 
 
Measurement of blood glucose concentrations 
Attention also has to be paid to the nature of the blood analysed i.e. arterial or venous, 
plasma or whole blood as this will affect the results obtained. Arterial blood sampling 
remains the “gold standard” but is a painful and difficult procedure to perform. Many 
studies including those from our own centre, have used arterialised venous blood 
sampling, where venous blood is taken from a hand that is placed within a heated box to 
increase blood flow and create a partial arteriovenous shunt [16]. This attempts to 





Plasma glucose concentrations are also 10-20% higher than contemporaneously 
measured whole blood concentrations [17]. 
 
 
Limitations of neuropsychological testing 
 
Studies of the effects of hypoglycaemia on cognitive function have to utilise 
neuropsychological tests. There is currently no consensus as to how many cognitive 
function tests make a minimum appropriate assessment of cognitive function. Is it more 
appropriate to use one test repeatedly or a battery of tests? The tests themselves such as 
the commonly used 4 Choice reaction time (4CRT) and Stroop ink colour tasks also 
measure multiple cognitive domains and not one single domain. The 4CRT for instance 
requires the domains of attention, visual information processing, central processing and 
psychomotor function in order to execute the task. Therefore if a deterioration is 
observed during hypoglycaemia it is impossible to ascertain whether this is due to an 
impairment in one, some or all domains. The artificial setting of the laboratory also 
limits the nature of the tests that can be administered as volunteers are either sitting in a 
chair or lying in a bed with one arm immobilised due to the intravenous infusions of 
insulin and dextrose.  If glycaemic thresholds for cognitive dysfunction are being 
examined then the tests also have to be quick to administer to allow for serial testing 
The transferability of the observed deterioration during hypoglycaemia  in certain 
cognitive function tests to activities of daily living that people with diabetes have to deal 
with during episodes of hypoglycaemia are also questionable. Some tests such as the 
driving simulator studies by Cox and colleagues whereby driving performance was 
impaired by mild hypoglycaemia (3.6 mmol/l in the earlier study and ~3.0 mmol/l in 
the latter), with a tendency to veer off course, drive too fast and brake inappropriately 





important, do not have the same relevance during an episode such as acute 
hypoglycaemia. Performance in most tests will improve with practice therefore the 
results of the tests obtained during hypoglycaemia must be compared to those obtained 
at similar time points during euglycaemia and not simply compared to those obtained at 
baseline which was an inherent problem in many earlier studies. In addition the studies 
should be counterbalanced with half of the subjects undergoing the hypoglycaemia 
session first followed by the euglycaemia session and vice versa. 
Finally many moderators of cognitive function exist such as the presence of diabetes, 
antecedent hypoglycaemia, glycaemic control, baseline IQ will affect performance on 
tasks and these will be discussed in detail in Chapter 3. 
 
2.2   Cognitive Domains Affected by Acute Hypoglycaemia 
 
There is an extensive literature on the effects of acute hypoglycaemia, but as discussed 
above differing methodology can make comparing studies difficult, with the reported 
results varying widely. However a few important conclusions can be drawn. Studies with 
a higher cognitive load appear more susceptible to neuroglycopenia than simple tasks. 
Finger tapping, a simple motor task appears to be relatively unaffected by 
hypoglycaemia in healthy volunteers and in people with diabetes at a blood glucose 
concentration of 3.1 and 2.0 mmol/L [20-22]. Simple reaction time to either a light or 
sound appears only to deteriorate below 2.7 mmol/L in non-diabetic volunteers [23-25] 
but 4 Choice reaction time (with 4 potential responses) is reported to be affected at a 
blood glucose of 3.2 mmol/L [26,27]. Similar trends have been observed in people with 





Cognitive function appears to be consistently affected at a blood glucose below 2.9 
mmol/L with a deterioration in speed of arthrimetic calculation, verbal fluency, colour 
identification, trail making, digit symbol test performance, digit span and memory 
function all reported [29,30]. Non-cognitive effects such as a change in mood with an 
increase in tense arousal and a decrease in energetic arousal are also reported [31].  
Table 2.1 examines the effects of moderate hypoglycaemia in healthy volunteers. Table 
2.2 the effect in adults with type 1 diabetes. Studies examining the effects of moderators 
of cognitive function were not reviewed as these are discussed in Chapter 3. Studies 
examining between group differences (healthy volunteers versus people with Type 1 
diabetes) were also not examined.  
The tables are by no means a complete synopsis of this area, as this has been 





Table 2.1: Data from studies examining the effects of hypoglycaemia on various aspects of cognitive dysfunction in healthy volunteers 
 
Study Stevens et al (1989) Blackman et al 
(1990) 
Kerr et al (1993) McCrimmon et al 
(1997) 
Evans et al  (2000) McAulay et al 
(2001) 
Sommerfield et al 
(2003) 




















Yes Yes Yes Yes Yes Yes Yes Yes 
No of 
subjects 
12 19 10 20 8 20 16 16 
Age (years) 
(Median) 
23 (range 18-27) 26.8 (1.3) Range 20-33 27 (range 21-42) 28.5 (3.5) 28.7 (5.3) 29.6 (2.9) NR 
Cognitive 
tests  
FTT, TMB, DSS, 
CFFT, CRT, 
auditory and visual 
RT 





4 CRT, Stroop, 
TMB  
TEA, RPM AVLT, LMT, TMB, 
DSS, BVRT, WMT 





3.4 mmol/L 2.6  mmol/L 32.8 mmol/L 2.6 mol/L 2.6 mmol/L 2.6 mmol/L 2.6 mmol/L 2.5 mmol/L 
Outcome Decrease in DSS, 
TMB 
Increase in P300 
latency and simple 
RT 
Increase in P300 
latency 








Decrease in DSS, 
TMB, Working and 
delayed memory 
Decrease in TMB, 








Table 2.2: Data from studies examining the effects of hypoglycaemia on various aspects of cognitive dysfunction in people with type 1 
diabetes 
Study Holmes et al (1983) Holmes et al (1984) Holmes et al (1986) Pramming et al  
(1986) 
Ewing et al  (1998) Strachan et al (2002) Sommerfield et al  
(2003) 








No No No No Yes Yes  Yes 
No of 
subjects 
12 12 24 16 16 15 15 
Age (years) 
 
NR 18-35 years 21.3 28 (Range 20-46) 26.9 (Range 18-47) 26.5 (9.1) 28.5 (20.0-38.2) 
HbA1c  (SD)  NR NR 9.6 % 8.7 (Range 7.2-
10.1) 
8.5 (1.3) 8.8 (2.0) 8.2% (6.9-8.7) 
(Median  (Range) 
Duration of 
Diabetes  
NR NR 8.2 12 (range 4-28) 8.8 (Range 12-17) 11.1 (6.6) 4.5 (1.2-8.4) 
(Median  (Range) 
Cognitive 
tests  
AVLT, Digit supraspan, 




Simple RT, Choice 
RT, letter  
recognition, FTT 





processing test, TMB, 
DSS 
DSS, TMB, AERP, 
Auditory Information 
Processing. 
AVLT, LMT, TMB, 
DSST, BVRT, WMT 
Glucose 
Nadir  
3.3 mmol/L 3.0 mmol/L 3.0 mmol/L 2.0 mmol/L 2.6 mmol/L 2.6 mmol/L 2.5mmol/L  
Outcomes Decrease in RT and 
mathematical computation 
Decrease in verbal 
fluency 
Decrease in CRT Decrease in all 
tests 
Decrease in Visual IP, 
DSS, TMB  
Decrease in TMB, 
DSS and aspects of 
AP 
Decrease in short-term, 







Footnotes to tables 2.1 and 2.2: 
AERP = Auditory Event Response Potentials 
AH5=Alice Heim 5  
AP = Auditory Processing 
AVLT = Auditory Verbal Learning Test 
BVRT= Benton Visual Reproduction Test 
CRT=4 Choice Reaction Time     
DSS= Digit Symbol Substitution  
FTT = Finger Tapping Test 
IP = Information Processing 
LMT = Logical memory test 
MFFT = Matching Familiar Figures Test 
NDRT = Nelson Denny Reading Test 
RPP = Ravens Progressive Matrices  
RAPM = Ravens Advanced Progressive Matrices 
TEA= Tests of Everyday Attention 
TMB=Trail Making B   





2.2.1 Recovery of cognitive function after induction of hypoglycaemia 
 
Given the fact that the brain is almost entirely dependent on glucose for its energy, 
acute hypoglycaemia should lead to an almost instantaneous deterioration in cognitive 
function and as symptoms are generated centrally, symptomatic awareness of such an 
event [32,33]. Evans and colleagues induced hypoglycaemia (blood glucose nadir 2.6 
mmol/L) in 8 healthy volunteers [34]. After 90 minutes the blood glucose concentration 
was then rapidly restored. Cognitive function (4 CRT, Stroop and Trail Making B), 
symptoms and counter regulatory responses were assessed throughout the test period.  
There was statistically significant impairment of cognitive function immediately, whereas 
counter regulation and symptoms only achieved significance at 20 minutes.  It therefore 
appears that neuroglycopenia develops even in people with normal awareness of 
hypoglycaemia before symptoms of low blood glucose develops. 
Recovery of cognitive function is generally thought to occur between 45-90 minutes 
after blood glucose concentrations are returned to normal [23,24,35,36]. The latest study 
to examine this came from Zammitt and colleagues in Edinburgh [37]. They examined 
the effect of acute hypoglycaemia (nadir 2.5mmol/L) on recovery of cognitive function 
in 20 people with normal awareness of hypoglycaemia and demonstrated that a 
deterioration in choice reaction time persisted for up to 75 minutes after correction of 
hypoglycaemia (Figure 2.1). Earlier studies whose results have to be interpreted with a 







Figure 2.1: Mean (SE) times on Choice Reaction Time and Trail Making B  













































2.3 Effect of hypoglycaemia on cognitive function 
 
Studies have indicated that people with diabetes have a relatively poorer cognitive ability 
than matched controls [39,40]. The aetiology behind this is probably multifactoral 
including chronic hyperglycaemia, recurrent diabetic ketoacidosis, exposure to severe 
hypoglycaemia, hypertension, cerebrovascular disease etc however most of the research 
has focused on the role of severe hypoglycaemia. 
Strachan and colleagues examined the effect of a single episode of spontaneous severe 
hypoglycaemia on cognitive function and mood state [41]. Twenty subjects with insulin 
treated diabetes and a recent hypo where compared to 20 subjects who had not had an 
episode of severe hypoglycaemia within the preceding year. Subjects were matched for 
baseline IQ, age, sex and duration of diabetes. Subjects were examined at three time 
points following the event, on average 1.5, 8.9 and 30 days. The participants completed 
an extensive battery of cognitive function tests including: NART, WAIS-R, TMB, 
Forward and backward digit span, logical memory, figural memory, visual change 
detection, verbal fluency test, PASAT, CRT, Stroop test and various mood and anxiety 
scores. At the first time point only one (block design) out of the 14 cognitive function 
tests demonstrated any difference between the two groups suggesting recovery of 
cognitive function occurs up to 36 hours after the initial event. Although rare single 
episodes of very severe hypoglycaemia have been reported to lead to permanent damage 
due to neuronal necrosis [42]. 
Exposure to recurrent severe hypoglycaemia in retrospective cross-sectional studies has 
suggested that this leads to cognitive impairment. Wredling and colleagues examined 
cognitive function in 17 adults with type 1 diabetes and a history of severe 





severe hypoglycaemia. Participants were matched for age, sex, duration of diabetes, 
educational achievement, employment status and presence of microvascular 
complications [43].  The cohort with exposure to severe hypoglycaemia performed 
statistically worse on several cognitive function test including digit symbol. The study 
design did not preclude the possibility that the patients who had a history of recurrent 
hypoglycaemia may have been those who had a lower pre-morbid IQ and, being less 
adept in their self-management of diabetes, had therefore experienced a higher 
frequency of severe hypoglycaemia. Sachon and colleagues studied 30 patients with 
insulin dependent diabetes and 30 without a history of severe hypoglycaemia. In 
addition 25 non-diabetic controls were studied [44]. The patients with previous severe 
hypoglycaemia performed worse on several cognitive function tests (trail making, verbal 
fluency and memory) however those with a history of hypoglycaemia were significantly 
older than those without which could have affected the results obtained. Langam and 
colleagues from Edinburgh demonstrated a significant correlation between intellectual 
impairment and history of severe hypoglycaemia in a group of one hundred people with 
type 1 diabetes [45]. Intellectual impairment was calculated as the difference between 
pre-morbid cognitive function assessed via the National Adult Reading Test (which 
correlates highly with IQ and is resistant to the effects of organic brain damage, and 
thus may represent ‘best ever’ intelligence) and current performance IQ [46]. Further 
sub-group analysis, splitting the cohort into quartiles on the basis of their previous 
experience of severe hypoglycaemia, revealed that those with five or more episodes of 
severe hypoglycaemia compared to those with no previous severe hypoglycaemia, a 
significant difference was observed in IQ deficit (approximately 6 IQ points), 
performance IQ and reaction times, (Figure 2.2). While this study indicated a 





it could not exclude the possibility that diabetes per se was affecting cognitive function. 
In a follow up study by Deary and colleagues the same 100 subjects with type 1 diabetes 
were compared to a group of 100 non-diabetic controls, matched for sex, age, years of 
education and social class [47]. No difference was also observed in NART scores and 
thus pre-morbid IQ. This study demonstrated that the performance and verbal IQs of 
the diabetic participants were lower than the non-diabetic controls. Once the effects of 
severe hypoglycaemia were controlled for the difference in performance IQ between the 
healthy volunteers and subjects with diabetes was abolished. The significant between 
group differences in verbal IQ persisted after controlling for severe hypoglycaemia 
suggesting additional factors. 
Similar results delineating a correlation between decline in performance IQ and 


















Figure 2.2.  No significant difference in pre-morbid (black bars) and current IQ 
(white bars) was demonstrated in Group A (no previous SH) but a significant 
difference was demonstrated in those with > 5 previous episodes of SH, p < 







































Cross-sectional studies however have their limitations. Firstly an association can be 
implied by the results obtained not causality. Secondly between group comparisons can 
introduce potential cofounders unless the groups are meticulously matched as cognitive 
function is known to be affected by variables such as age, gender, concurrent medical 
conditions, medication, alcohol and drug ingestion etc. Thirdly many of the above 
studies did not match the groups for pre-morbid IQ i.e. best achievable IQ which is 
preserved even in generalised cognitive decline. Lastly the frequency of severe 
hypoglycaemia has to be estimated retrospectively and this has been shown to be 
reliable for up to one year after the event [49].  Therefore the self-reported “lifetime” 
frequency of severe hypoglycaemia has to be interpreted with caution. 
Prospective studies therefore would appear to allow causality to be drawn whilst 
minimising the confounding variables as subjects are acting as their own controls. The 
largest prospective trials of type 1 diabetes are the Diabetes Control and Complications 
Trial (DCCT) [50] and the Stockholm Diabetes Intervention Study (SDIS) [51].  Both of 
these studies were designed to evaluate the effect of strict glycaemic control on limiting 
the complications of diabetes. The participants were subdivided into intensively-treated 
and conventionally-treated subgroups, achieving either strict or moderate glycaemic 
control respectively, the incidence and progression of diabetic complications and the 
frequency of adverse effects of treatment were monitored prospectively. Both studies 
have shown unequivocally that strict glycaemic control limits the development and 
progression of diabetic microangiopathy, but is accompanied by a higher rate of severe 
hypoglycaemia. 
In the DCCT patients underwent detailed cognitive function testing at entry and at three 
other points (two, five and seven years later) with an average of 6.5 years.  In the SDIS 





function testing in the SDIS was more limited. In both studies no association between 
episodes of severe hypoglycaemia and cognitive decline was demonstrated [50,51].  The 
cognitive evaluation carried out as part of the DCCT was repeated 12 years after the trial 
ended as part of the Epidemiology of Diabetes Intervention and Complications (EDIC) 
study [52]. Follow up data was available for 1144 patients (85% of the original cohort) 
assessed on average 18 years after the start of the trial. Again there was no difference in 
cognitive function between participants allocated to either conventional or intensive 
treatment with no association between frequency of severe hypoglycaemia and cognitive 
change. These results appear to suggest that strict glycaemic control and the almost 
inevitable severe hypoglycaemia risk that accompanies this leads to minimal or no effect 
on cognitive function. The participants enrolled into the DCCT as discussed previous 
are somewhat atypical of the general population with diabetes. They were relatively 
young and had diabetes of short duration. They were also above average intelligence, 
were highly motivated and were well educated in self-care of their diabetes. People who 
had a history of multiple episodes of severe hypoglycaemia were excluded. This criterion 
is likely to have excluded anyone with impaired hypoglycaemia awareness, so that few, if 
any, patients were recruited to participate in these studies who were at high risk of 
developing severe hypoglycaemia, thus not surprisingly the annual rate of hypoglycaemia 
reported was about half that from studies of unselected individuals with type 1 diabetes. 
This makes it difficult to translate these results to an average diabetic population 









2.4    Effect of hypoglycaemia on brain structure  
 
Profound, protracted severe hypoglycaemia while uncommon can lead to permanent 
neurological and cognitive deficits [42]. Anecdotal case reports of individuals who 
suffered from protracted severe hypoglycaemia revealed localised neuroimaging 
abnormalities predominantly affecting the frontal lobes and deep grey matter [53-59].  In 
rat studies, exposure to a single episode of severe hypoglycaemia lasting between 10-60 
minutes lead to widespread neuronal damage, the extent of which correlated with 
duration of exposure to hypoglycaemia [53]. The pattern of neuronal damage was not in 
keeping with that found after exposure to ischaemia and raised the possibility of 
neuronal damage secondary to release of excitotoxins such as glutamate and aspartate. 
Potentially therefore exposure to repeat episodes of moderate hypoglycaemia could lead 
to neuronal damage. 
Permanent EEG changes (an increase in frontal slow activity and a decrease in alpha 
frequency) have been demonstrated in those with recurrent severe hypoglycaemia [60-
63]. Acute hypoglycaemia in known to increase cerebral blood flow, particularly to the 
frontal lobes [64]. MacLeod and colleagues in Edinburgh examined 20 subjects with 
type 1 diabetes (10 of whom had a history of exposure to severe hypoglycaemia) and 20 
age & sex matched healthy volunteers [65]. Cerebral blood flow was assessed by SPECT 
with 99mTechnetium Exametazime. An alteration in the pattern of baseline regional 
cerebral blood flow was observed in the patients with diabetes with frontal excess and 
relative posterior reduction in cerebral blood. Results were more pronounced in those 
with a history of severe hypoglycaemia. Similar results from the same group were 





Whether or not hypoglycaemia leads to structural changes in the brain is less clear cut. A 
small study of 11 people with type 1 diabetes and no severe hypoglycaemia and 11 with 
>5 episodes of severe hypoglycaemia since diagnosis revealed that cortical atrophy was 
more prevalent in subjects with recurrent severe hypoglycaemia [67]. In another later 
study from our centre no association was observed between previous severe 
hypoglycaemia and structural abnormalities of the brain using MRI [68]. Unlike the 
previous study no relationship was identified between severe hypoglycaemia and cortical 
atrophy. The later study had significantly more participants (71 compared to 22 in the 
previous study) and studied a younger population. The main finding was that chronic 
hyperglycaemia (inferred by background retinopathy) was associated with small 
punctuate white matter lesions in the basal ganglia and periventricular regions. Those 
with background retinopathy also performed less well on cognitive function tests 
suggesting the observed results were secondary to “diabetic encephalopathy”, to which 




Data from cross-sectional studies in adults with type 1 diabetes have suggested that 
exposure to recurrent hypoglycaemia may lead to a modest impairment of cognitive 
ability. Whether this small (a 0.33-0.5 decrease in standard deviation) reported reduction 
in cognitive ability would translate into deterioration of activities of daily living for 
people with type 1 diabetes remains unlikely. The two prospective studies (including the 
EDIC follow up) provide some reassurance that exposure to severe hypoglycaemia will 
generally on the whole not lead to significant cognitive impairment. There are however 





dysfunction whilst others are relatively unaffected after exposure to severe 
hypoglycaemia.  
Results from neuroimaging studies again offer confirmation that exposure to severe 
hypoglycaemia does not on the whole, unless severe and protracted, lead to structural 
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3.1  Background 
 
Hypoglycaemia frequently occurs in insulin-treated diabetes [1,2], and can impact upon 
all aspects of life [3]. While hypoglycaemia impairs cognitive function [4], not all 
cognitive domains are affected equally [5-11]. Considerable inter-subject variability exists 
in the magnitude of cognitive impairment [9,12-18], and several moderators influence 
the susceptibility of an individual’s cognitive performance to the effects of 
hypoglycaemia.   
The search for moderators that predict individual vulnerability assumes that this clinical 
response to hypoglycaemia is consistent across time and equivalent degrees of 
hypoglycaemia, and that it does not simply reflect individual variation within a 
population.  Gonder-Frederick and colleagues [19] used a battery of cognitive tests to 
study 26 adults with type 1 diabetes at three levels of blood glucose (6.3, 3.6 and 2.6 
mmol/l); the tests were repeated following restoration of euglycaemia.  To assess the 
temporal reliability of individual differences of deterioration in performance during 
hypoglycaemia, 15 of the subjects were re-tested after three months.  Considerable 
variation was demonstrated between the subjects’ responses to hypoglycaemia [19].  At a 
blood glucose of 3.6mmol/l, 19% of the subjects exhibited a significant deterioration in 
cognitive performance, while almost half were unaffected, but at 2.6 mmol/L a 
significant deterioration occurred in more than 50% of the subjects; only 15% exhibited 
preservation of performance.  On subsequent re-testing, individual variations in 
vulnerability to, and the degree of, cognitive dysfunction, were unchanged, indicating 
that individual differences to hypoglycaemia are stable and do not occur at random.  
This suggests that there are stable individual differences in susceptibility to the cognitive 





The factors that account for the individual differences to hypoglycaemia-induced 
cognitive dysfunction are of clinical importance in type 1 diabetes and various 
moderators have been identified.   
 
3.2   Age 
 
Age influences the counterregulatory and symptomatic responses to hypoglycaemia. In 
older people, the magnitude of adrenaline (epinephrine) and glucagon responses is 
lower, autonomic symptoms are less profound and neuroglycopenic symptoms 
predominate [20-24]  (Figure 3.1).  One small study utilised the four-choice reaction 
time, a test of co-ordination and psychomotor speed, to examine the effects of ageing 
on the glycaemic thresholds for cognitive impairment during controlled hypoglycaemia 
in two groups of non-diabetic men [24], seven aged 60-70, and seven aged 22-26 years.  
Blood glucose was lowered in a stepwise manner from 5.0 to 2.4 mmol/l, and at each 
plateau the counterregulatory hormones, symptoms, and four-choice reaction time were 
assessed.  degree.  In the younger group, the symptoms of hypoglycaemia commenced 













Figure 3.1:  The difference between the glycaemic threshold for 
subjective awareness of hypoglycaemia and that for the onset of cognitive 


























In the older men, no discernible difference was observed between the blood glucose 
thresholds for onset of the symptoms of hypoglycaemia and cognitive impairment.  
Thus the opportunity to detect and self-treat hypoglycaemia before more disabling 
neuroglycopenia supervened was less in the older subjects. These age-related differences 
in the glycaemic thresholds for symptom generation and cognitive impairment during 
hypoglycaemia may put older people at greater risk of severe hypoglycaemia, through 
inability to identify early hypoglycaemia.  
Other studies have shown no consistent correlation between age and the degree of 
cognitive impairment during hypoglycaemia, but the differences in age between the 
subjects were modest [17,19]  with an upper age limit of 52 years, which may have 



















3.3   Gender 
 
Significant gender differences in cognitive performance during acute hypoglycaemia and 
hyperglycaemia were demonstrated in a study of 20 men and 22 women with type 1 
diabetes [17] , in whom many cognitive abilities were tested, including sensory 
perceptual processing, simple motor abilities, attention, learning and memory, language, 
and spatial and constructional abilities. Patients were examined at plasma glucose levels 
of 2.2, 5.6 (euglycaemia), 8.9 (baseline), 14.4, and 21.1 mmol/l.  All measures of 
cognitive performance were impaired at 2.2 mmol/l when compared with the baseline 
performance. The performance decrement of cognitive impairment from baseline 
(where no gender differences were observed) in the tests, which examined selective and 
sustained attention (digit vigilance test) and mental flexibility (trail making B), was less in 
women and this difference persisted after adjustment for other potential confounding 
factors.  No gender differences were observed with tests of other aspects of cognitive 
function, nor was this discrepancy evident in the cognitive test scores at lesser levels of 
hypoglycaemia.  However these results have to be interpreted with care as only 10 
subjects underwent a separate euglycaemia clamp. The indication of a gender difference 
in cognitive susceptibility to hypoglycaemia is supported by a further study that 
demonstrated that women performed better on cognitive function testing than men 
during mild hypoglycaemia (venous plasma glucose 3.6 mmol/l) [19]. However, in this 
study, the degree of cognitive impairment was similar in both sexes during more 
profound hypoglycaemia (blood glucose 2.6 mmol/l). The fact that hypoglycaemia 
appears to cause less cognitive dysfunction in females could potentially explain the 
lower incidence of severe hypoglycaemia rates in the female participants in the 





Paradoxically other studies have shown that women have less intense counterregulatory 
hormonal response than males, although the glycaemic thresholds at which these 
responses are triggered are similar in both sexes [26-28]. No difference between the 
sexes was also reported in the hypoglycaemia symptom scores of 160 subjects, including 
non-diabetic volunteers and people with type 1 diabetes, in whom controlled 
hypoglycaemia had been induced [29]. 
 
3.4   Intelligence 
 
It has been suggested that highly intelligent individuals possess more ‘brain reserve 
capacity’ for cognitive processing, that will confer protection if cognitive function is 
compromised during cerebral insults such as hypoglycaemia [30] .  Gold and colleagues 
[31]  examined whether IQ level exerts a differential effect on hypoglycaemia-induced 
cognitive dysfunction by studying 24 healthy non-diabetic volunteers, subdivided into 
groups with high and average IQ. The latter was determined using two standard tests of 
general intelligence (the Alice Heim 4 test and the National Adult Reading Test).  
Cognitive function was measured during euglycaemia (plasma glucose 4.5 mmol/l) and 
during hypoglycaemia (plasma glucose 2.5 mmol/l). At baseline, the high IQ group 
demonstrated a significantly better performance in most of the cognitive tasks, but 
during hypoglycaemia cognitive function deteriorated irrespective of IQ, and very few 
differences were observed between the two groups in performance in the cognitive 
tasks. Multiple univariate analysis of variance revealed an influence of IQ on the 
hypoglycaemia effect on two of the cognitive tests.  During hypoglycaemia, the group 
with average IQ deteriorated significantly less than the high IQ group in the tests of 





and Rapid Visual Information Processing).  This could have been a type 1 statistical 
error.   These results suggest that individuals with a higher IQ are not protected from 
the adverse effects of hypoglycaemia on cognitive function, and that they may in fact be 
more vulnerable to the detrimental effects of neuroglycopenia on intellectual ability.  
Studies of cognitive performance during hypoglycaemia in people with diabetes have 
not shown a relationship with intelligence, or a surrogate marker such as the number of 
years of education [9.17.19], but only a small number of studies have examined this 
possibility. 
 
3.5   Diagnosis of Diabetes 
 
Whether diabetes per se influences cognitive performance during hypoglycaemia has 
been addressed by measuring cognitive function before, during, and after acute insulin-
induced hypoglycaemia (arterialised blood glucose 1.8-2.0 mmol/l) in 10 men with type 
1 diabetes and in 12 non-diabetic men, matched for age and baseline performance on a 
variety of cognitive tests [32].  At euglycaemia, no between-group differences in 
cognitive performance were apparent; during hypoglycaemia cognitive performance 
deteriorated significantly in both groups.  However, during hypoglycaemia a greater 
degree of cognitive impairment occurred in those with type 1 diabetes, suggesting that 
diabetes confers greater susceptibility to neuroglycopenia.  This could represent a 
“diabetic encephalopathy”, developing as a consequence either of repeated exposure to 
severe hypoglycaemia or from the effects of chronic hyperglycaemia [32,33].  However, 
cognitive function at baseline did not differ between the two groups and the diabetic 





hypoglycaemia, necessitating a greater reduction in blood glucose to achieve equivalent 
hypoglycaemia. This may have influenced the magnitude of cognitive impairment.  
In two other studies no differences between diabetic and non-diabetic subjects were 
noted in cognitive performance during acute hypoglycaemia [10,16], and in a further 
study of diabetic and non-diabetic subjects [34], differences in cognitive performance 
between the groups were observed at baseline, thus precluding interpretation of the 
effects of diabetes on responses during hypoglycaemia.   
 
3.5.1  Other Diabetes-Related Clinical Variables 
 
No relationship has been observed between the degree of cognitive dysfunction during 
hypoglycaemia and variables such as duration of diabetes [16,17,21,35], age of onset of 
diabetes [18,19], and the magnitude of the counterregulatory hormonal responses to 
hypoglycaemia [9,16,].  A greater deterioration in cognitive performance during acute 
hypoglycaemia in people with type 1 diabetes was associated with a history of previous 
hypoglycaemia coma [19,20]. 
 
3.5.2  Glycaemic Control 
 
Strict glycaemic control alters the glycaemic thresholds at which symptomatic and 
counterregulatory hormonal responses to hypoglycaemia are initiated, requiring lower 
blood glucose to trigger these responses [37,38].  However, evidence that the threshold 
for the cognitive dysfunction during hypoglycaemia is modified by the nature of 





Cognitive function during hypoglycaemia was compared in eight subjects with type 1 
diabetes with good glycaemic control (mean HbA1 8.0%) and nine subjects with poor 
glycaemic control (mean HbA1 11.8%) [10].  The median blood glucose for the 
threshold for cognitive dysfunction did not differ between the groups. Similar results 
were observed when the four-choice reaction time was measured during acute 
hypoglycaemia in eight subjects with type 1 diabetes who had good glycaemic control 
(mean HbA1c 7.7%) and 10 who had sub-optimal control (mean HbA1c 10.1%) [39]. 
Several other studies [10.14,31,40] have shown no correlation with quality of glycaemic 
control.  
Measurement of event-related potentials can provide an objective quantitative 
assessment of cognitive function.  The P300 component of these sensory evoked 
potentials is generated endogenously when a subject is required to discriminate and 
memorise a specific task-specific stimulus.  Its latency reflects the speed of information 
processing and correlates with attention and short-term memory. Ziegler and colleagues 
[40] examined the effect of glycaemic control on P300 event-related potentials during 
hypoglycaemia.  Eighteen people with type 1 diabetes were studied, seven of whom had 
a mean HbA1c of 6.3% while 11 had a mean HbA1c of 9.1%.  No significant difference 
in P300 latency between the two groups was present at baseline. However, the glycaemic 
threshold at which a significant increase of P300 latency was first detected was 1.6 
mmol/l in subjects with strict glycaemic control, and 3.5 mmol/l in those with poorer 
control. A study that examined the effect of hypoglycaemia on P300 potentials in people 
with intensively and conventionally treated diabetes reported similar results [41]. Thus, 
neurophysiological measurements suggest that glycaemic control can influence blood 
glucose thresholds, and may be more sensitive than cognitive tests. A significantly 





hypoglycaemia in 15 subjects with type 1 diabetes who had strict glycaemic control 
(mean HbA1c 6.9%) compared with subjects with less strict glycaemic control (mean 
HbA1c 8.8%) [13].  The subjects with strict glycaemic control had a history of more 
episodes of hypoglycaemic coma, which may have influenced their performance 
 
3.6    Antecedent Hypoglycaemia 
 
The thresholds for counterregulatory hormonal responses to hypoglycaemia are 
modified by preceding exposure to hypoglycaemia (antecedent hypoglycaemia), [42,43], 
but its impact on the glycaemic threshold for cognitive dysfunction is difficult to assess; 
different degrees and durations of antecedent hypoglycaemia have been studied, and the 
interval between the episode of antecedent hypoglycaemia and subsequent exposure to 
further hypoglycaemia has varied considerably between studies, so preventing 
comparison. 
Nine non-diabetic volunteers were exposed to antecedent hypoglycaemia (arterialised 
blood glucose 3.2 mmol/l) or euglycaemia (blood glucose 5.2 mmol/l) for two hours, 
before a stepped hypoglycaemic clamp was performed 90 minutes later. Cognitive 
function was assessed using Logical Memory, a test of immediate verbal memory and 
the Digit Symbol Substitution Test, a test of general psychomotor performance [44].  
During the later hypoglycaemia, equivalent deterioration of the Digit Symbol 
Substitution Test scores occurred irrespective of exposure to antecedent hypoglycaemia 
or euglycaemia, but the performance during hypoglycaemia in the logical memory task 
was preserved following antecedent hypoglycaemia.  This suggests that an adaptive 
response to exposure to low blood glucose allowed the preservation of memory during 





Asymptomatic nocturnal hypoglycaemia is very common in type 1 diabetes [45,46], and 
its impact on cognitive function has been examined during hypoglycaemia induced the 
following morning.  Veneman and colleagues [47] measured cognitive function during 
hypoglycaemia in 10 healthy volunteers after induction of asymptomatic nocturnal 
hypoglycaemia (plasma glucose 2.4 mmol/l) for two hours, and also after a euglycaemia 
study in which saline was infused overnight instead of insulin. When hypoglycaemia was 
induced on the following morning, cognitive dysfunction was significantly less after the 
antecedent nocturnal hypoglycaemia, compared to nocturnal euglycaemia.  In addition, 
the plasma glucose concentration at which cognitive dysfunction developed was 
significantly lower following antecedent hypoglycaemia.  Fanelli and colleagues [48] also 
demonstrated that a single episode of moderate (and asymptomatic) antecedent 
nocturnal hypoglycaemia caused less cognitive dysfunction during a subsequent episode 
of controlled hypoglycaemia the following day.  In this study, the effect of antecedent 
nocturnal hypoglycaemia (arterialised plasma glucose 2.8 mmol/l) was examined in 15 
people with type 1 diabetes.  The subjects were exposed to either nocturnal 
hypoglycaemia or euglycaemia for 3.5 hours.  When cognitive function was tested 
during hypoglycaemia induced on the following day, cognitive dysfunction was less 
severe after nocturnal hypoglycaemia compared with nocturnal euglycaemia. In 
particular, there was relative preservation in performance of tasks assessing attention 
and pattern recognition, but not in tasks of delayed verbal memory and information 
processing. These studies suggest that after recent antecedent hypoglycaemia the 
glycaemic thresholds for hypoglycaemia-induced cognitive dysfunction are shifted to 
lower plasma glucose concentrations.     
 By contrast, a study of 16 non-diabetic subjects by Hvidberg and colleagues [49] 





were not altered after a period of antecedent hypoglycaemia.  In the afternoon, the 
subjects were exposed for two hours to either moderate hypoglycaemia (mean blood 
glucose 2.6 mmol/l) or, on a separate occasion, to euglycaemia (4.8 mmol/L).  The 
following morning, cognitive function tests assessing information processing, attention, 
pattern recognition and memory were administered during controlled hypoglycaemia.  
No significant effect overall of exposure to antecedent hypoglycaemia was observed on 
subsequent hypoglycaemia-induced cognitive dysfunction.  However, when 
performance of individual tasks at specified blood glucose concentrations was 
examined, the deterioration in tasks of attention and pattern recognition was less when 
the plasma glucose concentration was reduced from 2.8 to 2.5 mmol/l.   
No effect of antecedent hypoglycaemia on hypoglycaemia-induced cognitive 
dysfunction has been found in other studies.  Dagogo-Jack et al exposed 16 people with 
type 1 diabetes either to antecedent hypoglycaemia or to euglycaemia induced during the 
afternoon [50]. Cognitive function during hypoglycaemia induced on the following 
morning was not affected significantly by the antecedent hypoglycaemia.  Indeed, 
deterioration in some aspects of cognition such as attention was greater following 
antecedent hypoglycaemia.  In another study [51], eight people with type 1 diabetes were 
exposed to antecedent hypoglycaemia (arterialised blood glucose 2.8 mmol/l) or 
euglycaemia (blood glucose 5.0 mmol/l), which was followed, after an interval of two 
days, by a further episode of hypoglycaemia. The four-choice reaction time test was 
used to examine cognitive function, and the decrement in performance in response to 
hypoglycaemia was unaffected by exposure to antecedent hypoglycaemia, despite 
blunting of the noradrenaline response to antecedent hypoglycaemia. Other studies 
[52,53] reported that antecedent nocturnal hypoglycaemia had no effect on cognitive 





Finally, a study by Ovalle and colleagues [54] investigated the impact of recurrent 
antecedent hypoglycaemia on cognitive performance during subsequent stepped 
hypoglycaemia. Six patients with type 1 diabetes were exposed either to two hours of 
recurrent hypoglycaemia (blood glucose 2.8 mmol/l) or to two hours of hyperglycaemia 
(8.3 mmol/l) twice weekly, for a period of one month.  Following recurrent antecedent 
hypoglycaemia, cognitive function during hypoglycaemia was significantly less impaired.    
Some evidence exists that the glycaemic thresholds for the impairment of cognitive 
function may be shifted to commence at lower blood glucose concentrations in people 
who are exposed to recurrent hypoglycaemia, but definitive studies are awaited. 
 
3.7    Duration of hypoglycaemia: (short-term cerebral adaptation)      
 
The brain appears to have an inherent ability to adapt to repeated exposure to low blood 
glucose and function normally although the supply of glucose is limited. This is apparent 
by the shift of the glycaemic thresholds for counterregulatory hormonal secretion and 
symptom generation to lower blood glucose levels. The glycaemic threshold for the 
onset of cognitive dysfunction may also be modified, but this is less certain.  The 
putative mechanism underlying cerebral adaptation is unknown but may involve up 
regulation of glucose transporters, which control the rate of glucose transport into 
neurones or an enhanced ability to use alternative fuels. 
In two separate studies by Kerr and colleagues, performance in a simple reaction time 
test was studied during prolonged hypoglycaemia in people with [55], and without [56] 
type 1 diabetes.  Arterialised blood glucose concentration was clamped at 3.5 mmol/l 
for one hour then reduced to, and maintained at, 2.8 mmol/l for 90 minutes in the 





diabetes [56].  Reaction times were measured at baseline, and twice at each glucose 
plateau. Initially these reaction times slowed when the blood glucose concentration was 
lowered from 3.5 mmol/l to the blood glucose nadir, compared to the baseline scores.  
However, after prolonged exposure to hypoglycaemia the reaction times improved 
towards those achieved at baseline, in parallel with a fall in symptom score.  Therefore, 
as hypoglycaemia continued, symptomatic awareness declined and cognitive function 
appeared to improve, while counterregulatory hormones remained elevated.  The 
findings of these studies [55,56] have been interpreted as demonstrating some degree of 
cerebral adaptation during mild hypoglycaemia.  However, apart from the inadequacy of 
the cognitive assessments, the study design is fundamentally flawed. Many cognitive 
functions are not impaired until blood glucose reaches a level lower than 2.8 mmol/l, 
and a separate euglycaemia condition in the same subjects indicated that the reaction 
time changes were associated with a practice effect, so that the performance improved 
with increasing application.  No statistical comparison of the results from the 
hypoglycaemia and euglycaemia clamps was provided.   
By contrast, Gold and colleagues [57] found no evidence of cerebral adaptation in 24 
non-diabetic subjects following exposure to 40-60 minutes of hypoglycaemia 
(arterialised blood glucose 2.5 mmol/l). This study was more scientifically robust in that 
an extensive cognitive test battery was utilised, with statistical adjustment for potential 
practice effects by comparing the hypoglycaemia clamp results with those obtained 
during a separate euglycaemic clamp.  However, the duration of hypoglycaemia (60 
minutes) was relatively short; a longer period of exposure to hypoglycaemia may be 
necessary to induce cerebral adaptation. 
The effect of prolonged hypoglycaemia on cerebral adaptation was investigated by Boyle 





hypoglycaemia for four days.  On the first day, a stepped hypoglycaemic clamp was 
performed, lowering blood glucose concentration from 4.7 to 2.5 mmol/l.  At each 
plateau of blood glucose, measurements were made of hypoglycaemia symptoms, 
counterregulatory hormones, cognitive function and brain glucose uptake.  The 
arterialised blood glucose concentration was maintained at 2.9 mmol/l for 56 hours.  
On the final day, experimental hypoglycaemia was repeated.  The glycaemic thresholds 
at which the subjects developed symptoms, released counterregulatory hormones and 
developed cognitive dysfunction had shifted to lower blood glucose levels compared to 
the first hypoglycaemia study.  In the first study, brain glucose uptake (determined by 
measuring glucose concentrations in arterial and jugular venous blood, and multiplying 
the difference by the cerebral blood flow, estimated by a tracer method) became 
impaired at a blood glucose concentration of 3.6 mmol/l, but on the final day it was 
preserved throughout hypoglycaemia.  Adaptation appears to have occurred within the 
brain following prolonged exposure to a low blood glucose level, so preserving brain 
glucose uptake and protecting cerebral function during hypoglycaemia.  However results 
must be interpreted with caution possible practice effects of the cognitive tasks were not 
evaluated, and the statistical analysis compared cognitive performance at each blood 
glucose level within a clamp with its own baseline.  Interaction analyses between the 
clamps were not performed, thereby increasing the risk of a spurious effect emerging in 
line with the experimental hypothesis.   
 
3.8    Impaired awareness of hypoglycaemia 
 
Assessment of the effect of impaired awareness of hypoglycaemia on cognitive function 





condition.  Moreover, it is difficult to separate the confounding influences of recent 
antecedent hypoglycaemia and strict glycaemic control, which are inter-related.  The 
effects of insulin-induced hypoglycaemia on subjective detection of hypoglycaemia, and 
on cognitive function using the four-choice reaction time test, were studied in 15 people 
with type 1 diabetes [35].  Blood glucose was lowered to 2.5 mmol/l and maintained at 
this level for 30 minutes.  Subjects were asked if they felt hypoglycaemic and to score 
symptoms. At a blood glucose of 2.5 mmol/l, only four of the 15 subjects recognised 
that their blood glucose was low.  The subjects were not matched for IQ, and those 
who had impaired awareness of hypoglycaemia had a longer duration of diabetes and 
lower mean glycated haemoglobin than the subjects with normal awareness.  Cognitive 
performance was affected to the same degree during hypoglycaemia in the subgroup 
with intact symptomatic awareness, compared to the larger number with impaired 
awareness.  This study indicates that the glycaemic threshold for the generation of 
symptoms varies between individuals, and is influenced by glycaemic control and factors 
such as duration of type 1 diabetes, but actual impairment of hypoglycaemia awareness 
was not demonstrated.  
Zammitt and colleagues [59] have shown that the decrement in cognitive ability during 
hypoglycaemia is less in people with impaired awareness compared to subjects who have 
normal awareness of hypoglycaemia.  Twenty subjects with type 1 diabetes and normal 
self-assessed hypoglycaemia awareness (12 male, median HbA1c 8.7%, median age 30 
years) and 15 subjects with impaired hypoglycaemia awareness (6 male, median HbA1c 
8.2%, median age 34 years) were exposed to euglycaemia (blood glucose 4.5 mmol/l) 
and hypoglycaemia (2.5 mmol/l).  The hypoglycaemia-aware group suffered impairment 
of short-term verbal memory at 2.5 mmol/l, whereas the unaware group did not.  This 





By contrast, in an earlier study also from our centre, Gold and colleagues [60] 
demonstrated that people with type 1 diabetes with impaired awareness of 
hypoglycaemia [61] exhibited a trend towards greater cognitive dysfunction during acute 
hypoglycaemia, which persisted for longer following restoration of euglycaemia, 
compared to subjects with normal awareness.  The aware and unaware subjects in this 
study were matched for pre-morbid IQ, duration of diabetes, HbA1c and exposure to 
previous episodes of hypoglycaemia.  There was, however, a difference in IQ between 
the two groups (0.5 standard deviation), with the unaware subjects having lower mean 
scores on the Alice Heim 4 task (a test of general intelligence).  Although this difference 
was not statistically significant, it may have confounded the study results. 
Symptomatic awareness of hypoglycaemia may be restored in people who have impaired 
awareness of hypoglycaemia if hypoglycaemia is avoided [62].  Studies examining the 
effect of the restoration of hypoglycaemia awareness on the glycaemic thresholds for the 
development of cognitive dysfunction during acute hypoglycaemia have demonstrated 
conflicting results.  Cranston and colleagues [63] investigated the effects of avoiding 
hypoglycaemia in 12 men with type 1 diabetes, aged 28-55 years, who had a duration of 
diabetes between 11 and 32 years. All had impaired awareness of hypoglycaemia, but six 
had strict glycaemic control (mean HbA1c 6.5%) and six had a higher mean HbA1c 
(8.2%).  After a period of avoidance of hypoglycaemia for three weeks (which took a 
mean of four months to achieve), the hormonal and symptomatic responses to 
controlled hypoglycaemia both increased in magnitude.  However, the glycaemic 
threshold for cognitive dysfunction (assessed solely by the four choice reaction time 
test) did not change, with deterioration in cognitive function occurring at similar blood 
glucose concentrations (2.8 mmol/l) in all patients, before, and after, the period of 





restoration of awareness of hypoglycaemia was associated with a change in the 
glycaemic threshold for cognitive dysfunction during acute hypoglycaemia in 16 people 
with type 1 diabetes, all of whom had impaired awareness of hypoglycaemia.  Cognitive 
function during, and symptomatic awareness of, hypoglycaemia were measured before, 
and after a period of avoidance of hypoglycaemia for two weeks.  Counterregulatory 
hormonal and symptomatic responses to hypoglycaemia improved following 
hypoglycaemia avoidance, and the blood glucose at which cognitive dysfunction 
commenced was higher after the period of avoidance of hypoglycaemia.  In addition, 
the degree of cognitive dysfunction was less at a given glucose concentration.  These 
changes were maintained following a year of hypoglycaemia avoidance [64], and were 
also observed in subjects with impaired awareness of hypoglycaemia who had type 1 
diabetes of short duration [65]. 
Similar observations were made by Mitrakou and colleagues [66] in non-diabetic people 
with insulinomas who were exposed to chronic hypoglycaemia. Surgical resection of the 
tumour reversed impaired awareness of hypoglycaemia and deficient counterregulation, 
while cognitive dysfunction became more evident during hypoglycaemia. 
 
3.9    Pharmacological agents 
 
Structural similarities exist between the pancreatic beta cell and glucose-sensitive 
neurones within the hypothalamus, and sulphonylurea receptors are widely distributed 
in neuronal cells throughout the brain. Agents that alter membrane channels for 
potassium adenosine triphosphate (KATP) in pancreatic beta cells have been shown to 
improve cognitive function during acute neuroglycopenia. In a study of 10 non-diabetic 





threshold of 2.5 mmol/l during treatment with glibenclamide, compared to of 3.0 
mmol/l with diazoxide and at 2.9 mmol/l with placebo [67].  
Although the brain primarily relies on glucose under periods of prolonged fasting or 
during hypoglycaemia it can utilise alternative fuels which potentially could protect 
cognitive function during hypoglycaemia. Evans and colleagues [68], used a 
hyperinsulinaemic glucose clamp to lower plasma glucose to 2.5 mmol/l while infusing 
intravenous alanine or saline in seven non-diabetic males. Cognitive function, assessed 
by the Stroop colour-word test, deteriorated less during alanine compared to saline 
infusion, although performance in several other cognitive tests did not improve. Alanine 
may be utilised by the brain as a metabolic fuel during hypoglycaemia in place of 
glucose, or may enable an increased availability of lactate. Page and colleagues from Yale 
examined the effects of medium chain fatty acids, which are rapidly metabolised into 
ketones, in their ability to protect cognitive function during a hyperinsulinaemic glucose 
clamp [69] . Using a battery of tests to assess multiple cognitive domains they 
demonstrated that ingestion of the medium chain fatty acids lead to preservation of 
cognitive performance in the domains of immediate verbal memory, delayed verbal 
memory, verbal memory recognition, DSS and total map searching. Reassuringly the 
medium chain fatty acids had no effect on the adrenergic hormonal or symptomatic 
response to hypoglycaemia. Similar results were also observed by Rossetti after oral 
administration of amino acids  [70]. 
Modafinil inhibits the release of the inhibitory neurotransmitter gamma-aminobutyric 
acid (GABA), and its effects on cognitive function during acute hypoglycaemia have 
been studied [71]. Nine healthy male volunteers were randomly assigned to take either 
200mg of modafinil or a placebo, following which euglycaemia was maintained or 





performance during euglycaemia. However, in the modafinil-treated group performance 
in two cognitive function tasks (the Stroop colour-word test and simple reaction time) 
deteriorated less during hypoglycaemia. 
Alcohol and hypoglycaemia independently affect cognitive function adversely. Cheyne 
and colleagues [72] demonstrated that the additive effects of hypoglycaemia and alcohol 
in 17 healthy subjects who were studied during (a) euglycaemia (blood glucose 4.5 
mmol/l) with placebo, (b) euglycaemia with alcohol, (c) hypoglycaemia (2.8 mmol/l) 
with placebo and (d) hypoglycaemia with alcohol. The blood alcohol concentration was 
identical both arms at 43 mg/dl (2.4mmol/l). The administration of alcohol during 
euglycaemia was associated with deterioration in performance in the Four-Choice 
Reaction Time and Trail Making B tests, while the hypoglycaemia and placebo arm was 
associated with deterioration in performance in the Four-Choice Reaction Time test 
alone. However, when alcohol was combined with hypoglycaemia the deterioration in 
performance in all of the cognitive function tests was significantly augmented. 
 Caffeine heightens the symptomatic and counterregulatory responses to hypoglycaemia, 
thereby increasing recognition of hypoglycaemia, and several studies have examined the 
potential effect of caffeine on cognitive function. One study [73] showed a very small 
improvement in performance in a single cognitive test (the Four-Choice Reaction Time 




Acute hypoglycaemia has a significant effect on mood [4,76-81].  Changes in emotions 
are common and may influence cognitive performance during hypoglycaemia.  





energy, and even irritability and anger.  Considerable inter-individual differences are 
observed in the effects of hypoglycaemia on mood and it appears that an idiosyncratic 
relationship exists in individual subjects between mood and low blood glucose.  This 
discrepant effect between individuals may have a direct influence on their cognitive 
performance during acute hypoglycaemia. 
 
3.11   Conclusions  
 
Moderators of cognitive performance during hypoglycaemia may have important 
influences on people with insulin-treated diabetes in relation to their performance 
during driving or at work, which can be affected adversely by exposure to 
hypoglycaemia.  
Individual differences in susceptibility to the effects of acute hypoglycaemia on 
cognitive function may be mediated by interacting factors.  Increasing age and male 
gender may increase susceptibility to the effects of hypoglycaemia on intellectual 
function and, less convincingly, the presence of diabetes per se and higher intelligence 
may confer a greater predilection for cognitive impairment in the presence of 
neuroglycopenia.  However, in type 1 diabetes, the duration of the disorder, the age of 
onset and the integrity of the hormonal counterregulatory responses to hypoglycaemia 
do not appear to be important determinants of the nature or degree of cognitive 
decrements during hypoglycaemia. Furthermore, evidence exists that prolonged or 
repeated exposure to moderate hypoglycaemia induces cerebral adaptation as manifested 
by a subsequent improvement in cognitive performance or the absence of any adverse 





The impact of impaired awareness of hypoglycaemia, strict glycaemic control and 
antecedent hypoglycaemia on the ability of the brain to adapt to frequent exposure to 
neuroglycopenia remains undecided.  Some studies have supported the premise that the 
glycaemic thresholds for the impairment of different domains of cognitive function are 
shifted to commence at lower blood glucose concentrations in people who are exposed 
to recurrent hypoglycaemia, in a manner analogous to the shift in glycaemic thresholds 
for counterregulatory hormonal and symptomatic responses. However, a shift in 
glycaemic thresholds for cognitive dysfunction has not been demonstrated consistently.  
After discounting investigations that have obvious methodological limitations, most 
studies demonstrating a shift in cognitive thresholds have utilised either a battery of 
cognitive function tests or neurophysiological tests that measure changes in sensory 
evoked potentials.  By contrast, the studies that did not demonstrate any change in 
glycaemic thresholds have usually utilised a single or, at most, two cognitive tasks [11] .  
It is likely that not all cognitive tests are affected to a similar degree by conditions such 
as impaired awareness of hypoglycaemia, strict glycaemic control or recurrent 
antecedent hypoglycaemia, so that limited cognitive testing may be inadequate to 
demonstrate an effect on glycaemic thresholds [82].   
 With studies that are appropriately counterbalanced, robust effects of moderate 
hypoglycaemia on a number of cognitive domains can be found. However, identifying 
the reasons for individual differences in these effects is more difficult. The study designs 
are largely between-subjects as opposed to within-subjects, which have less power. 
Furthermore, the difference in an effect between two groups typically will be relatively 
small. These facts combine to make the discovery of the factors underlying differences 
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4.1 Research Aims 
 
4.1.1 Hypoglycaemia and cognitive function 
 
As human brain is dependent on a continuous supply of glucose as its main source of 
energy, cerebral deprivation of glucose rapidly causes cognitive dysfunction through the 
direct effects of acute neuroglycopenia [1,2]. An extensive body of literature already 
exists on the effects of hypoglycaemia on cognitive function. The aims of the following 
studies were to investigate the effects of hypoglycaemia on as yet unexplored aspects of 
cognitive function and apply novel methods of analysis to identify in greater depth the 
effects of hypoglycaemia on cognitive function. 
The effect of hypoglycaemia on psychomotor function, unlike other cognitive domains 
that have received detailed examination, has attracted very limited systematic study. 
Psychomotor performance encompasses motor strength, hand-eye co-ordination, 
balance, dexterity, tracking, and other skills. These skills are important for many 
common activities of daily life in which hand control and fine visuo-motor coordination 
play a critical role, during tasks such as driving and performance at work. 
The few studies that specifically have examined the effects of hypoglycaemia on 
psychomotor function have been limited by an inadequate degree of hypoglycaemia or 
by limitations in study design. Stevens and colleagues [3] examined the effects of 
experimentally-induced hypoglycaemia on psychomotor function, using the glucose 
clamp technique, in 12 adult healthy volunteers. The psychomotor test battery consisted 
of two simple reaction time tests, finger tapping test (FTT), trail making, critical flicker 
fusion (CFF), Digit Symbol (DS) and four-choice reaction time (4CRT). At a blood 
glucose nadir of 3.4 mmol/L two tests deteriorated significantly: trail making (p < 0.05) 





not be considered to be sufficiently low to significantly affect cognitive functions, as 
blood glucose needs to fall below 3.0 mmol/L before many cognitive domains are 
affected [4-7].   
The effects of hypoglycaemia on the PSE Syndrom-Test (consisting of DSS, Digit 
Connection, Aiming Centre I, Aiming Centre II, [requiring the subject to mark the 
centre of a fixed number of circles within an allocated time] and Line Tracing Time & 
Errors) were studied in 10 people with type 1 diabetes in a study by Lingenfelser and 
colleagues [8]. During hypoglycaemia a significant decrement was observed in fine 
motor skill and coordination (Aiming Centre I &II, Line Tracing Error tests). However 
the results must be interpreted with caution, because the participants did not undergo 
testing in a counterbalanced fashion, but were subjected to the euglycaemia test battery 
followed by the hypoglycaemia test battery during the same experimental session. This 
experimental design meant that by practice effects and fatigue were completely 
confounded with the experimental manipulation (euglycaemia versus hypoglycaemia). 
To perform a more comprehensive assessment of psychomotor function during 
hypoglycaemia it is necessary to examine aspects of sensory processing, the central 
integration and processing responses, overt motor responses and overall sensori-motor 
coordination [9], (Figure 4.1). Study participants usually tolerate controlled 
hypoglycaemia for a maximum of about one hour, so it is not feasible to examine all 
aspects of psychomotor function during one period of hypoglycaemia. Study 1 (chapter 
5) therefore examines the effects of acute, moderate, insulin-induced hypoglycaemia 
(blood glucose 2.5 mmol/L) on psychomotor functions, utilising a glucose clamp 
technique in a randomised, counterbalanced design, with particular attention placed on 
examining overt motor responses and overall sensori-motor coordination, as these have 





and people with type 1 diabetes to ascertain if any differences existed in the effects of 
hypoglycaemia on psychomotor function between the groups. 
 
Modelling the effects of hypoglycaemia on a two-choice task in adult 
humans 
As described above reaction time encompasses one aspect of psychomotor function. It 
is already known that hypoglycaemia causes reaction times to be slower and more 
variable [11].  In these studies, an overall test score was used, which reveals little about 
the precise effect of hypoglycaemia on reaction times, namely are the slowed reaction 
times secondary to the effects on overt motor skills, visual processing, central 
processing speeds etc. 
Mathematical sequential modelling techniques have been developed to allow data 
obtained from simple reaction time tasks to provide precise quantitative predictions of 
the relationships between mean reaction times and the probability of correct responses 
and errors, and the shapes of the reaction time distribution thus allowing for dissection 
of the above [12,13]. Study 2 (chapter 6) therefore examines the effects of applying this 
mathematical sequential modelling technique to data obtained during euglycaemia and 
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4.1.2 Impaired awareness of hypoglycaemia 
Despite the high prevalence of impaired awareness of hypoglycaemia in those with Type 
1 Diabetes, there is currently no international consensus on its definition or the best 
method for identifying those suspected of having this acquired condition. This 
syndrome theoretically could be identified subjectively via questionnaires administered 
in structured clinical interviews or objectively assessing counter regulation in the course 
of hypoglycaemic clamps or via continuous glucose monitoring. The most common 
questionnaire assessment methods used in both clinical practice and in population based 
studies are the methods of Clarke, Gold and Pederson Bjergaard [14-16].  The methods 
of Clarke and Gold are relatively similar in that they ascertain whether the person with 
type 1 diabetes has perceived any change in symptoms to the onset of hypoglycaemia 
and quantify the previous exposure to severe hypoglycaemia. The method of Pederson 
Bjergaard simply requires the patient to respond to the question “Do you have 
symptoms when you have a hypo?”, requiring the selection of one response from 
“always”, “sometimes” or “never”.   Only the patients who answer “always” are 
considered to have normal symptomatic awareness of hypoglycaemia, the others are 
designated as having impaired or absent awareness.   Studies from this group have 
reported rates of impaired/absent awareness of up to 59% of all clinic patients [17], 
which are far in excess of the expected rate of impaired awareness in a standard cohort 
with type 1 diabetes.   These rates may have occurred due to a very atypical patient 
population or due to the fact their simple method of identifying patients with impaired 
awareness of hypoglycaemia over-estimates the prevalence of this syndrome.   Study 3 
(chapter 7) compares the currently available methods in a randomly selected population 







The artificial nature of experimentally–induced hypoglycaemia using the glucose clamp 
technique, lends itself to being unsuitable for identifying impaired awareness for variety 
of reasons, such as the method of induction of hypoglycaemia, the supine posture, the 
delay in generating symptoms at different clamped blood glucose levels and so on. The 
ability of continuous glucose monitoring to differentiate between those with and 
without impaired awareness of hypoglycaemia will be examined in Study 4 (Chapter 8) 
with the hypothesis that those with impaired awareness of hypoglycaemia (as estimated 
from clinical characteristics associated with this syndrome and identification from a 
validated questionnaire) will have a higher rate of biochemical hypoglycaemia on CGM. 
The prevalence of impaired awareness of hypoglycaemia in Type 1 Diabetes has been a 
neglected area of research in recent years despite major advances that have been made 
in managing insulin-treated diabetes. These include the introduction of insulin analogues 
and CSII, the intensification of insulin regimens and innovative methods of patient 
education (such as DAFNE) which have been anticipated to have reduced overall 
exposure to hypoglycaemia, which we hypothesis should have led to a decline in the 
prevalence of IAH.  Study 5 (Chapter 9) examines the current prevalence of IAH in a 
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The effect of hypoglycaemia in causing cognitive dysfunction in general is well 
recognised. Recent studies have focused on how hypoglycaemia affects specific 
cognitive domains and the clinical relevance of any cognitive decrement that occurs [1-
5].   
Psychomotor function is an important domain of mental function that has not received 
systematic study with respect to the effect of hypoglycaemia. Psychomotor performance 
encompasses motor strength, hand-eye co-ordination, balance, dexterity, tracking, and 
other skills. Clearly, this range of motor and more psychomotor capabilities is important 
in many common everyday activities. Hand control, strength, and broad and fine visuo-
motor coordination play a vital role in driving, work performance and domestic life. 
During episodes of iatrogenic hypoglycaemia, people with insulin-treated diabetes 
frequently have reported a deterioration of fine motor skills [6].   
Previous studies of cognitive function during hypoglycaemia have occasionally included 
isolated psychomotor tests, but none has explored effects on this domain of 
psychological function comprehensively [7, 8, 9].  However, the few studies as discussed 
in Chapter 4 that have examined specifically the effects of hypoglycaemia on 
psychomotor function have been limited by a blood glucose nadir that would not be 
considered sufficiently low to have a significant effect on cognitive functions [10].  In 
other studies, a euglycaemia control arm was not incorporated in the study design, 
resulting in the effects of practice and fatigue being confounded by the experimental 
manipulation (euglycaemia versus hypoglycaemia) [11]. These problems were 







psychomotor function were measured during hypoglycaemia both in healthy non-
diabetic volunteers and in healthy adults with type 1 diabetes. 
 
5.2 Methods 
The study protocol was approved by the Lothian medical research ethics committee, 




Twenty (11 female) non-diabetic adults, (median (IQR) age 32 (27-35) years), and 
sixteen (8 female) adults with type 1 diabetes were studied. The subjects with type 1 
diabetes had a median (inter-quartile range) age of 40 (36-42.8) years, duration of 
diabetes of 15 (6-25) years and mean (SD) HbA1c of 8.2 (0.6) %.  No significant 
difference in age between the two groups (healthy non-diabetic volunteers or those with 
type 1 diabetes) was observed. HbA1c was measured by ion exchange high performance 
liquid chromatography via the Bio-Rad Variant II Haemoglobin testing system (non-
diabetic reference range 5.0-6.05%) and was DCCT-aligned.  None of the non-diabetic 
group had any previous medical history or a family history of diabetes, and none was 
taking regular medication (other than the oral contraceptive pill). As microvascular 
complications have been linked to a decrease in cognitive performance the subjects with 
type 1 diabetes had to have no evidence of microvascular complications, including 
diabetic retinopathy, peripheral neuropathy or nephropathy, the latter being defined by 
having a urine albumin: creatinine ratio persistently above the local reference range or a 
serum creatinine greater than 150 µmol/L. This, however, may not be representative of 







participants had impaired awareness of hypoglycaemia (IAH) as assessed by a validated 
method [12].  
 
5.2.2 Glucose clamp procedure 
Each subject participated in two laboratory sessions, each separated by at least two 
weeks. The studies were conducted in the Clinical Research Facility of the Royal 
Infirmary of Edinburgh. During the experimental visits, subjects underwent a modified 
hyperinsulinaemic glucose clamp [13]. The subjects completed both experimental 
conditions in a counterbalanced fashion, i.e. half of the subjects underwent the 
euglycaemia condition first followed by the hypoglycaemia condition and the other half 
underwent the experimental conditions in reverse order. The subjects were not 
informed which condition was being studied at each visit. 
Each session commenced at 8.00h following a 10 hour overnight fast. The subjects with 
type 1 diabetes administered their usual dose of insulin during the preceding evening, 
but no subcutaneous insulin was injected on the morning of the session. Studies were 
postponed if any of the subjects with type 1 diabetes developed either symptomatic or 
biochemical hypoglycaemia (blood glucose <4.0 mmol/L) during the 48 hours before 
each study. This resulted in one postponement.  A Teflon cannula was inserted into the 
ante-cubital vein under local anaesthetic (2% lignocaine). This cannula was used to 
infuse human soluble insulin (Actrapid, Novo Nordisk pharmaceuticals, Crawley, UK) 
and 20% dextrose. A second cannula was inserted in a retrograde direction into a vein 
on the dorsum of the hand, which was placed in a heated blanket to arterialise the 
venous blood. Arterialised blood samples were obtained throughout the study for the 







(Yellow Springs Instrument 2300 Stat, Yellow Springs, OH, USA). A modified 
hyperinsulinaemic glucose clamp technique (as described above) was used to maintain 
the blood glucose at predetermined levels. After a brief priming regimen, insulin was 
infused at a steady rate (based on whole body surface area) of 60 mU m -2 min  -1 using 
an IVAC Signature Gold pump (Alaris Medical Systems, San Diego, CA); 20% dextrose 
was infused, also using a IVAC Signature Gold pump, at a variable rate depending on 
the blood glucose value. Arterialised blood glucose was measured initially at every 3 min, 
until a stable level had been achieved, and then at 5-minute intervals. At each laboratory 
session, arterialised blood glucose was initially stabilised at 4.5 mmol/L for a period of 
30 minutes. Following this, the blood glucose concentration was either maintained at 4.5 
mmol/L (euglycaemia) or lowered to 2.5 mmol/L (hypoglycaemia) and the 
neuropsychological tests administered. The subjects were not informed about their 
blood glucose concentration during any phase of the study. A period of 20 minutes was 
allowed to elapse between the baseline and the attainment of euglycaemia or 
hypoglycaemia to allow the blood glucose concentration to stabilise. The target glucose 
concentration was maintained for a further 10 minutes before the tests were 
administered and was maintain for a further 60 minutes while the tests were 
administered. At the end of the hypoglycaemia session the blood glucose was restored 
to 4.5 mmol/L. Subjects were provided with a meal after completion of each condition. 
Epinephrine (adrenaline) and norepinephrine (noradrenaline) concentrations were also 
measured at baseline, 45 minutes into the experimental condition and at the completion 









5.2.3  Psychomotor tests 
 
4 Choice Reaction Time test – Reaction time is measured using a portable device, 
incorporating a high contrast LCD display screen at the top with response keys arranged 
below in a shallow arc (numbered 1, 2, 0, 3, 4) [14].   For four-choice reaction time, the 
subjects have to press the corresponding key when the one of the four digits (1, 2, 3 or 
4) appears on the screen. Mean and the standard deviation of the reaction times to 
correct trials (40 test trials, preceded by 8 practice trials) were recorded. 
 
Grooved Pegboard – The pegboard is a test of finger and hand dexterity, and is part of the 
Wisconsin Neuropsychological Test Battery [15]. The subject is presented with a small 
board consisting of a 5x5 set of slotted holes angled in different directions, which they 
complete with their dominant hand. Each peg has a ridge along one side requiring it to 
be rotated into position. The score is the time taken to complete the task. 
 
Tracing Test – This test assesses visuo-motor spatial ability [16]. Subjects are requested to 
draw a line using a digital pen (Anoto system) between two narrow parallel lines while 
avoiding random circles within the two lines. Accuracy is measured as the total number 
of times the line is crossed or a circle transected. Two scores are obtained, one for speed 
of completion in time and one for accuracy (errors).  
 
Pursuit Rotor (Lafayette Instruments, IN, USA) – This test examines hand-eye 
coordination and fine motor control. A light target rotates around a track (at a rotation 







movement. Performance is measured by the amount of time the subject can keep the 
stylus on the target (time on target) during one minute.  
 
Hand Steadiness (Lafayette Instruments, IN, USA) - The subject is required to place a 
metal tipped stylus in 9 progressively smaller holes without touching the sides. The 
stylus is held in position in each of the holes for 10 seconds. The impulse counter 
silently records activation if contact is made. The score is the total number of times the 
subject has touched the side of the holes for all nine holes. 
 
Static Balance – This was measured by static posturography via a force platform, designed 
to measure the position and the magnitude of the total vertical component of force 
applied to it [17]. Subjects were tested on a firm surface with their eyes open. During the 
period of measurement (one minute) the movement of the subject’s centre of mass was 
displayed on a computer screen and the corresponding total path length moved by the 
centre of mass was calculated. 
 
Hand grip (Lafayette Instruments, IN, USA) – A hand dynamometer was placed in the 
subject’s dominant hand at their side away from their body. The subject was instructed 
to squeeze the dynamometer as hard as possible, with no time constraint taking to reach 
the maximum grip. The score is the amount (in kg) registered at each of the three trials, 










5.2.4 Other tests 
 
These were performed as a validation check, to allow comparison of the effects of 
hypoglycaemia as had been demonstrated in previous studies in our laboratory [2,3,8]. 
 
Digit Symbol Test (DST). 
This test assesses sustained attention, speed of response and visual scanning [18]. 
 
5.2.5 Symptom scores 
 
The subjects scored the presence and intensity of symptoms of hypoglycaemia using the 
Edinburgh Hypoglycaemia Symptom Scale [19]. Symptoms of hypoglycaemia are 
classified as autonomic (hunger, palpitations, sweating, tremor), neuroglycopenic (confusion, 
drowsiness, difficulty concentrating, weakness) and malaise (nausea, headache). Subjects 
scored their symptoms of hypoglycaemia at baseline and at 45 minutes into the 
experimental period. 
 
5.2.6 Statistical analysis 
 
A general linear model (repeated measures analysis of variance [ANOVA]) was used, 
with order of session (euglycaemia-hypoglycaemia or hypoglycaemia-euglycaemia) as a 
between-subjects factor, and condition (euglycaemia or hypoglycaemia) as a within-
subject factor (repeated measure). In the full model, including the non-diabetic 
volunteers and adults with type 1 diabetes, subject group and order of session were 
between-subjects factor with condition as a within-subjects factor. A p value of less than 







squared (η2). The principal measures of interest were the eta squared representing the 
proportion of the variance in the test scores accounted for by study condition 
(euglycaemia vs. hypoglycaemia). All analyses were performed using SPSS version 12.0 




5.3.1 Blood glucose 
 
The mean (SD) fasting arterialised blood glucose in the group with type 1 diabetes was 
7.1 (1.1) mmol/L on the morning of the studies. In the non-diabetic group during 
euglycaemia the mean blood glucose concentration was 4.45 mmol/L (0.12) and during 
the hypoglycaemic condition, the mean (SD) blood glucose was 2.59 mmol/L (0.11), 
(Figure 5.1). In the subjects with type 1 diabetes during euglycaemia the mean blood 
glucose concentration was 4.47 mmol/L (0.10) and during the hypoglycaemic condition, 




The scores from the hypoglycaemia symptom questionnaire were significantly higher 
during hypoglycaemia in both groups for autonomic (p<0.001), neuroglycopenic 











5.3.3 Catecholamine concentrations 
 
Plasma concentrations of both epinephrine (p = 0.04), (Figure 5.3), and of 
norepinephrine (p =0.006), (Figure 5.4), were significantly higher during hypoglycaemia 
(t = 45 minutes) in the healthy volunteer group compared to the people with type 1 
diabetes. Similar results were found in the hypoglycaemia recovery period (Figure 5.3), 
but all other time points revealed no difference in the concentration of catecholamines 
between the groups. Correlations between plasma concentrations of epinephrine and 
hand steadiness were non-significant for both the healthy volunteer (rs = 0.46, p = 0.06) 




































Figure 5.1: Mean blood glucose concentrations (SD) during baseline and the 
study conditions of both the euglycaemic (●) and hypoglycaemic (▲) glucose 




























































Figure 5.2: Mean blood glucose concentrations (SD) during baseline and the 
study conditions of both the euglycaemic (●) and hypoglycaemic (▲) glucose 


































































Figure 5.3: Mean plasma epinephrine (adrenaline) concentrations (SD) during 





























































Figure 5.4: Mean plasma norepinephrine (noradrenaline) concentrations (SD) 
during study condition and recovery in both the healthy volunteers and people 































































5.3.4 General cognitive function tasks 
 
The mean (SD) score of the Digit Symbol test deteriorated from 92.7 (12.6) during 
euglycaemia to 82.5 (9.7) during hypoglycaemia, p <0.001, η2 = 0.624 in the non-diabetic 
group and from 81.4 (22.6) during euglycaemia to 73.3 (21.6) during hypoglycaemia, p 
<0.007, η2 =  0.445 in the group with type 1 diabetes. These findings confirm that the 
hypoglycaemic intervention had the expected effects comparable to previous studies of 
similar design [2, 3, 8]. 
 
5.3.5 Psychomotor tasks 
The results of mean (standard deviation) and eta squared of the psychomotor function 
test scores for the healthy volunteers (HV) and the people with type 1 diabetes (T1DM) 
during euglycaemia and hypoglycaemia (glycaemic status) are shown in table 5.1. The 
interaction between glycaemic status and group of subject (healthy volunteer or person 
with type 1 diabetes), was then also examined (Table 5.1) 
 
Statistical analysis confirmed that no significant order effects had occurred for any of 
the outcome variables of the study. 
 
Four choice reaction time 
Acute hypoglycaemia caused a significant increase in mean four choice reaction times, 
both in the non-diabetic group (p = 0.008, η2 = 0.36) and in the group with type 1 
diabetes (p = 0.02, η2 =0.34). The interaction between glycaemic state and subject group, 









In the test of hand dexterity, acute hypoglycaemia caused a significant increase in the 
time taken to complete the task in the non-diabetic group (p =0.004, η2 =0.37). In the 
group with type 1 diabetes no significant differences were observed between the two 
study conditions. (p =0.44, η2 =0.045). The interaction between glycaemic state and 
subject group, however was not significant (p = 0.38). 
 
Hand Steadiness 
The hand steadiness test demonstrated a significant decrement during hypoglycaemia (p 
= 0. 003, η2 =0.40) in the non-diabetic group.  No significant decrement in hand 
steadiness during hypoglycaemia was demonstrable in the group with type 1 diabetes (p 
= 0. 11, η2 =0.18). The glycaemia-group interaction achieved statistical significance 
suggesting that the effects of hypoglycaemia differed significantly between the groups (p 
= 0.021).   
 
Tracing time 
No significant change in performance was observed in tracing time, between the two 
study conditions, either in the non-diabetic group (p= 0. 480, η2 = 0.03) or in the group 
with type 1 diabetes (p = 0. 39, η2 = 0.06). Non-significant differences, were also noted 
with tracing time errors, in subjects with (p= 0.50, η2 =0.03), and without type 1 diabetes 
(p = 0.436, η2 =0.03). The interaction between glycaemic state and subject group, was 











Mean scores for time on target were significantly greater during euglycaemia compared 
to hypoglycaemia in the non-diabetic group (p = 0. 018, η2 =0.29) and in those with type 
1 diabetes (p = 0.04, η2 =0.27). The interaction between glycaemic state and subject 
group, was not significant (p = 0.59). 
 
Static Balance  
In the non-diabetic group, total body sway, assessed by static posturography, increased 
during hypoglycaemia under the condition of eyes open, (p = 0. 004, η2 =0.41). No 
significant change in total body sway, was observed in the group with type 1 diabetes, 
under the conditions of eyes open, (p = 0.34, η2 = 0.08). The glycaemia-group 
interaction achieved statistical significance suggesting that the effects of hypoglycaemia 
differed significantly between the groups (p = 0.042).   
 
Hand grip 
No significant deterioration of grip strength was observed during hypoglycaemia 
compared to euglycaemia (p =0.90, η2 =0.001) both in the non-diabetic group and in the 
group with type 1 diabetes (p =0.96, η2 =0.000). The interaction between glycaemic state 
















Table 5.1: Results (mean and (SD)) of tests of psychomotor function during euglycaemia (Eu) and hypoglycaemia (Hypo) in 20 non-
diabetic volunteers and 16 people with type 1 diabetes. 
 














576 (67) 616 (52) 0.008 .364  644 (10.) 687 (13) 0.023 0.340 0.762 0.003 
Grooved 
pegboard 
63.5 (9.0) 70.8 (8.6) 0.004 .371 69.7 (13.5) 72.2 (12.4) 0.443 0.045 0.376 0.025 
Hand-grip 
(kilograms) 
36.6 (8.9) 36.5 (9.3) 0.897 .001 40.8 (11.5) 39.4 (11.4) 0.961 0.000 0.902 0.000 
Hand 
Steadiness 
91. 8 (52.3) 179.4 (115.7) 0.003 .404 108.5 (39.4) 125.3 (22.8) 0.111 0.183 0.021 0.159 
Tracing time 
(seconds) 
64.1 (15.1) 62.1 (11.7) 0.480 .030 62.0 (12.2) 61.7 (13.6) 0.391 0.057 0.615 0.009 
Tracing time 
errors 
11.3 (9.5) 12.6 (8.6) 0.436 .034 16.6 (8.4) 19.1 (21.0) 0.504 0.035 0.702 0.005 
Pursuit Rotor 
(seconds) 
25.1 (6.8) 21.8 (9.6) 
 
0.018 .288 27.5 (10.5) 21.1 (10.2) 0.045 0.274 0.588 0.010 
Static balance 
with eyes open 
(meters) 
0.34 (0.12) 0.44 (0.17) 0.004 .414 0.39 (0.09) 0.40 (0.08) 0.337 
 









5.4.1 Psychomotor function 
 
In the present study hypoglycaemia appeared to exert a differing effect between the 
groups with regard to certain psychomotor tests (static balance and hand steadiness).  
The deterioration in the performance in DST in both groups during hypoglycaemia 
confirmed that the blood glucose was sufficiently low to impair cognitive function, and 
all subjects experienced symptoms of hypoglycaemia during the study.  
However in both groups, some cognitive tests were not affected by the moderate degree 
of hypoglycaemia, which included the line tracing and hand-grip tests. The hand-grip 
strength test is a simple, non-invasive measure of upper extremity muscle strength. The 
lack of an effect of hypoglycaemia on hand-grip function is consistent with a previous 
study which demonstrated that hypoglycaemia had no effect on the peripheral nervous 
system [18]. Tracing time was also not affected by moderate hypoglycaemia. This test of 
spatial ability, which has previously been demonstrated to be affected by moderate 
hypoglycaemia [20], is clearly too simplistic to assess this domain adequately. 
Scores on only two tests, the 4CRT and pursuit rotor, were significantly affected by 
hypoglycaemia in both groups. The effect sizes obtained for the euglycaemia-
hypoglycaemia comparison in the two studies showed almost identical effect sizes: for 
4CRT, eta2 = 0.36 in non-diabetic volunteers compared with eta2 = 0.34 in subjects with 
type 1 diabetes; and for pursuit rotor, eta2 = 0.29 in non-diabetic volunteers vs. eta2 = 
0.27 in subjects with type 1 diabetes. Previous research has demonstrated that recurrent 
exposure to hypoglycaemia can lead to preservation of cognitive function with regard to 







hypoglycaemia is induced slowly, it deteriorates at similar levels of blood glucose in 
most groups of subjects, irrespective of their previous glycaemic experience or state of 
hypoglycaemic awareness [22]. Given that no difference was observed in pursuit rotor 
results between the groups we would postulate that pursuit rotor also appears not to 
adapt to recurrent hypoglycaemia.  
The remainder of the tests namely hand steadiness, total body sway and grooved 
pegboard, revealed disparate results between the groups. All of the tests were 
significantly affected by hypoglycaemia in the non-diabetic group, with none being 
significantly affected in the group with type 1 diabetes. These findings appear to suggest 
that individuals with type 1 diabetes are less affected by hypoglycaemia than the healthy 
volunteers.  However, a conclusion that the effects of hypoglycaemia are significantly 
different between the two groups requires more than simply demonstrating that the 
effects are significant in one group and not the other. When rigorous statistical 
methodology is applied to test for any differences between the groups, a significant 
interaction between group status and glycaemic condition would have to be observed.  
This was significant for two out of the three tests: hand steadiness and total body co-
ordination (sway). This study therefore provides further evidence for a significant 
difference being exerted by hypoglycaemia when non-diabetic volunteers are compared 
with subjects who have type 1 diabetes. The mechanism behind this differing effect of 
hypoglycaemia on psychomotor function remains unknown, however may relate to the 
difference in sympatho-adrenal activation between the groups, a behavioural advantage 
in those with T1DM over the non-diabetic group derived from their previous exposure 








Hypoglycaemia is known to result in the activation of the autonomic nervous system 
with subsequent release of counterregulatory hormones. Recurrent exposure to 
hypoglycaemia (as would be expected in the group with type 1 diabetes) attenuates this 
response. The endogenous effects of autonomic activation that are manifested by 
sweating, shaking and a pounding heart, could therefore potentially interfere with 
psychomotor function such as hand-eye co-ordination and fine motor control. 
Therefore it is possible that the differences observed in the scores obtained in the 
pursuit rotor test and for hand steadiness may reflect the differing catecholamine 
responses to hypoglycaemia that were observed between the groups. However, the 
autonomic features result from central autonomic neural activation (via hypothalamic 
centres) [23] and, whereas the rise in plasma catecholamines augments the intensity of 
some autonomic manifestations such as a pounding heart and tremor, it is not the 
principal mediator. No significant correlations were demonstrable in the present study 
between the plasma concentrations of catecholamines and a test of fine motor control 
(hand-steadiness). However, the effect sizes were modest, and a larger study would be 
required to investigate this possibility further. Inevitably, the present study, though very 
powerful for the principal within-subjects analyses, provided less statistical power for 
correlation analyses. 
In non-diabetic volunteers and in people with type 1 diabetes, antecedent 
hypoglycaemia can alter the glycaemic thresholds for symptomatic and 
counterregulatory hormonal responses, re-setting these at lower blood glucose levels.   
In a small study of adults with type 1 diabetes (n=6), twice-weekly episodes of 
experimentally-induced hypoglycaemia over one month resulted in preservation of 
cognitive function (pattern recognition, memory, attention and information processing) 







transporters may contribute to the cerebral adaptation associated with recurrent 
hypoglycaemia [24] in humans it is not known whether regional brain differences in 
these processes might underlie differential adaptation of neurocognitive brain functions 
to recurrent hypoglycaemia [24].  
Another potential explanation could be that in the group with type 1 diabetes, previous 
experience of coping with the effects of hypoglycaemia may confer a behavioural 
advantage over the non-diabetic group. Direct observation of the subjects with type 1 
diabetes during administration of the cognitive function tests, gave the impression that 
they were concentrating on the tasks during hypoglycaemia with greater intensity than 
the hypoglycaemia-naïve, non-diabetic subjects. A previous clamp study by our group of 
16 adults with type 1 diabetes who had normal awareness of hypoglycaemia found no 
difference between the subjects in their perception of their ability to concentrate during 
the conditions of hypoglycaemia (2.5mmol/L) and euglycaemia (4.5mmol/L) [25]. 
Whether a difference in ability to concentrate during hypoglycaemia occurs between 
people with type 1 diabetes and hypoglycaemia-naïve, non-diabetic subjects remains to 
be explored.  
Subjects of both sexes participated in the present study.   Gender differences have been 
observed previously in the counterregulatory hormonal responses to hypoglycaemia [26-
30], but the symptomatic responses do not differ [31].   The evidence for a gender 
difference in degree of cognitive impairment is equivocal.   In one study of non-diabetic 
young adults, cognitive impairment was less in women than in men in tests of selective 
and sustained attention and mental flexibility [32], while in a different study, this 
cognitive advantage in women was observed only at very mild hypoglycaemia, with no 







exclude a gender difference in the effect of hypoglycaemia on psychomotor function, 
this is unlikely to be substantial at the degree of hypoglycaemia tested.  
Caution should however be exercised before concluding that the effects of 
hypoglycaemia differed significantly between the two groups. While the size of the 
groups in the present study was well powered to examine the effect of hypoglycaemia 
within these groups, statistical power was insufficient for formal between-group 
comparisons. Given the effect sizes observed, to have high power to detect a medium 
effect this would require more than 60 subjects in each group, which would be very 
demanding to accommodate when performing studies of this nature.  However, despite 
these reservations, the subjects with type 1 diabetes who had normal awareness of 
hypoglycaemia, appeared to be relatively resistant to the effects of hypoglycaemia on 
many aspects of psychomotor function. 
 
 5.4.2  Conclusions 
 
In conclusion, the present study has demonstrated that moderate acute insulin-induced 
hypoglycaemia exerted a differing effect between the groups to certain tests of 
psychomotor function. The difference in response to hypoglycaemia between the 
healthy volunteers and people with type 1 diabetes was in some part unexpected and 
thus warrants further investigation utilising PET or functional magnetic resonance 
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Modelling the Effects of Hypoglycaemia on a Two-






































The glucose clamp technique [1] has been used to study the effects of hypoglycaemia, 
typically compared with a counterbalanced euglycaemic state, on a range of cognitive 
and motor functions. These range from practical tasks to more information processing 
oriented measures. Hypoglycaemia causes deterioration in aspects of driving [2], which 
is of interest for reasons of health and safety and for legal reasons. Such high-level 
performance says little that is specific about the more precise brain functions that are 
affected. At a more basic level hypoglycaemia is known to cause deterioration in 
psychometric and neuropsychological tests assessing the cognitive domains of memory 
[3-5], attention [6, 7], reasoning [7], and psychomotor function [8]. At an even lower 
level, hypoglycaemia causes reaction times to be slower and more variable [9.10], and 
visual [11] and auditory [12] information processing becomes less efficient. The latter 
studies used tasks from psychophysics and experimental psychology. Even in these 
studies, an overall test score was used, not precise parameters related to cognitive 
processing stages. To date, there have been no studies that have examined the effects of 
hypoglycaemia on a task that assesses basic parameters of decision-making. Such 
fundamental information about the effect of fuel deprivation on the brain’s basic 
capabilities would be useful both for basic brain science and for applied research. Here, 
for the first time, we examine the effects of hypoglycaemia on a task which has validated 
information processing parameters. The task itself is a numerosity discrimination task in 
which a 10x10 array is presented on a computer screen with between 31 and 70 asterisks 
placed randomly. The subject is required to decide whether the number of asterisks is 






6.1.2 The diffusion model 
 
The diffusion model apportions parameter values to data from the relevant cognitive 
task and uses the parameter values representing the components of processing to 
interpret, for example, the effects of aging or sleep deprivation on performance [13-24]. 
The model (Figure 6.1) assumes that evidence from the stimulus is noisy and it is 
accumulated from a starting point (z) toward one or the other of the boundaries (a or 0). 
The mean rate of accumulation of evidence is called drift rate (v) and the assumption 
here is that the perceived numerosity is mapped into drift rate. Within-trial variability 
(noise) causes processes with the same drift rate to terminate at different times 
(producing RT distributions) and sometimes to terminate at the wrong boundary 
(producing errors). The values of the components of processing vary from trial to trial. 
Drift rate is assumed to be normally distributed across trials with SD η. Starting point is 
assumed to be uniformly distributed across trials with range sz (which is equivalent to 
variability in decision criteria if the variability is not too large). Contaminant responses 
are modeled by assuming that on some proportion of trials (po), there is a random delay 
added to the decision RT, due to a moment’s distraction, lack of attention, and other 
factors. The distribution is assumed to be uniform, but recovery of diffusion model 
parameters is robust to the actual form of the distribution [24] (Figure 6.1). 
In signal detection theory, all variability would be attributed to the numerosity estimate 
(the estimate of whether the number of asterisks was larger or smaller than 50) with 
variability normally distributed across trials. In the diffusion model, this corresponds to 
variability in drift rate across trials. However, in the diffusion model, the different 
sources of variability, within-trial, starting point, and the nondecision component are 





the model and the model is fit back to the predicted data, the parameter values are 
recovered accurately so that, for example, high variability in drift across trials is not 
misidentified as high variability in starting point [25] 
For this numerosity discrimination experiment, we assume that drift rates are equal and 
opposite for small responses to small stimuli and large responses to large stimuli. For 
example, the drift rate for 31-35 asterisks has the same numerical value as the drift rate 
for 66-70 asterisks. However, subjects can have a bias in the zero point of drift, so we 
use a drift criterion to be added to each drift rate [25]. The addition of a positive drift 
criterion, for example, makes a drift rate for the condition with 31-35 asterisks larger 
numerically than the drift rate for the condition with 66-70 asterisks. For further details 



















Figure 6.1: An illustration of the diffusion model with starting point z, boundary 









































The study protocol was approved by the Lothian medical research ethics committee, 
and all subjects gave informed consent for participation. 
 
6.2.1 Subjects 
Fourteen non-diabetic adult humans (5 male) were recruited from members of staff at 
the Royal Infirmary of Edinburgh. None had any relevant previous medical history of 
family history of diabetes, and none were taking regular medication (other than the oral 
contraceptive pill). All subjects had a corrected visual acuity of 6/6 or greater in both 
eyes, as measured with the Snellen chart. The median (inter-quartile range, IQR) age was 
28 (27-35) years and the mean body mass index (SD) was 22.8 (2.61) kg m-2. All of the 
subjects had above average intellectual ability as assessed by the National Adult Reading 
Test (NART) [26]. The mean (SD) NART correct score for 14 subjects was 41.5 (4.2). 
 
6.2.2 Glucose clamp procedure 
Each subject participated in two laboratory sessions, each separated by at least two 
weeks. The studies were conducted in the Clinical Research Facility of the Royal 
Infirmary of Edinburgh. During the experimental visits, subjects underwent a modified 
hyperinsulinaemic glucose clamp. The subjects completed both experimental conditions 
in a counterbalanced fashion. The subjects were not informed which condition was 





Each session commenced at 8.00h following a 10 hour overnight fast. A Teflon cannula 
was inserted into the ante-cubital vein under local anaesthetic (2% lignocaine). This 
cannula was used to infuse human soluble insulin (Actrapid, Novo Nordisk 
pharmaceuticals, Crawley, UK) and 20% dextrose. A second cannula was inserted in a 
retrograde direction into a vein on the dorsum of the hand, which was placed in a 
heated blanket to arterialise the venous blood. Arterialised blood samples were obtained 
throughout the study for the measurement of whole blood glucose at the bedside using 
a glucose oxidase method (Yellow Springs Instrument 2300 Stat, Yellow Springs, OH, 
USA). A modified hyperinsulinaemic glucose clamp technique (as described above) was 
used to maintain the blood glucose at predetermined levels. After a brief priming 
regimen, insulin was infused at a steady rate (based on whole body surface area) of 60 
mU m -2 min  -1 using an IVAC Signature Gold pump (Alaris Medical Systems, San 
Diego, CA); 20% dextrose was infused, also using a IVAC Signature Gold pump, at a 
variable rate depending on the blood glucose value. Arterialised blood glucose was 
measured initially at every 3 min, until a stable level had been achieved, and then at 5-
minute intervals. At each laboratory session, arterialised blood glucose was initially 
stabilised at 4.5 mmol/L for a period of 30 minutes. Following this, the blood glucose 
concentration was either maintained at 4.5 mmol/L (euglycaemia) or lowered to 2.5 
mmol/L (hypoglycaemia) and the neuropsychological tests administered. The subjects 
were not informed about their blood glucose concentration during any phase of the 
study. A period of 20 minutes was allowed to elapse between the baseline and the 
attainment of euglycaemia or hypoglycaemia to allow the blood glucose concentration to 
stabilise. The target glucose concentration was maintained for a further 10 minutes 
before the tests were administered and was maintain for a further 60 minutes while the 





restored to 4.5 mmol/L. Subjects were provided with a meal after completion of each 
condition. 
 




For each trial, a number of asterisks between 30 and 70 were generated from a signal 
distribution. The asterisks were placed in random positions in a 10 × 10 array of 
blank characters on a computer screen (Sony Vaio TR2A Notebook). The subjects 
were asked to decide whether the number of displayed asterisks was "large" or 
"small" by pressing the "Z"  key on the computer keyboard for the "large" group and 
the "?" key on the keyboard for the "small"   Accuracy feedback was given on all 
trials. There were 12 blocks of 50 trials per session. For the data analyses, the 
numbers of asterisks were grouped into eight experimental conditions so that the 
mean RTs and accuracy values were about the same for the stimuli within a group. 
 
Digit Symbol Substitution Test 
The Digit Symbol Substitution Test consists of eight rows containing, in total, 200 small 
blank squares, each with a randomly assigned number from 1 to 9. Above these rows is 
a printed key that pairs each number with a different symbol. The subject is asked to fill 
in as many of the blank squares as possible with the appropriate symbol that matches 
the number above the box, in a time limit of 120 seconds. The score is the number of 
squares that are completed successfully within the time limit. This test is performed 
routinely during hypoglycaemia clamp experiments as a validity check on the cognitive 





6.2.4 Symptom scores 
 
The subjects scored the presence and intensity of symptoms of hypoglycaemia using the 
Edinburgh Hypoglycaemia Symptom Scale [27]. Symptoms of hypoglycaemia are 
classified as autonomic (hunger, palpitations, sweating, tremor), neuroglycopenic (confusion, 
drowsiness, difficulty concentrating, weakness) and malaise (nausea, headache). Subjects 
scored their symptoms of hypoglycaemia at baseline and at 45 minutes into the 
experimental period. 
 
6.2.5 Statistical analysis 
 
A general linear model (repeated measures analysis of variance [ANOVA]) was used, 
with order of session (euglycaemia-hypoglycaemia or hypoglycaemia-euglycaemia) as a 
between-subjects factor, and condition (euglycaemia or hypoglycaemia) as a within-
subject factor (repeated measure). A p value of less than or equal to 0.05 was considered 
to be significant. Effect sizes were calculated using eta squared (η2). The principal 
measures of interest were the eta squared representing the proportion of the variance in 
the test scores accounted for by study condition (euglycaemia vs. hypoglycaemia). All 
analyses were performed using SPSS version 12.0 for Windows (SPSS Inc., Chicago, IL, 
USA). 
 
The diffusion model was fit to the data by minimizing a chi-square value with a general 
SIMPLEX minimization routine that adjusts the parameters of the model until it finds 
the parameter estimates that give the minimum chi-square value (26). The data entered 





0.9 quantile RTs for correct and error responses and the corresponding accuracy values. 
The quantile response times and the diffusion model were used to generate the 
predicted cumulative probability of a response by that quantile response time. 
Subtracting the cumulative probabilities for each successive quantile from the next 
higher quantile gives the proportion of responses between adjacent quantiles. For the 
chi-square computation, these are the expected values, to be compared to the observed 
proportions of responses between the quantiles (i.e., the proportions between 0, 0.1, 0.3, 
0.5, 0.7, 0.9, and 1.0, which are 0.1, 0.2, 0.2, 0.2, 0.2, and 0.1) multiplied by the number 
of observations. Summing over (Observed-Expected)2/Expected for all conditions gives 
a single chi-square value to be minimized. When there were too few observations (e.g., 
less than 5) for the extreme low error conditions for some of the subjects to form 
quantiles, a single chi-square value based on the response proportion alone was added to 




6.3.1 Blood glucose 
All results are reported as mean (SD) unless otherwise stated. A stable blood glucose 
plateau was achieved during both study conditions. The mean (SD) blood glucose 
concentration during the euglycaemia condition was 4.58 mmol/L (0.18), and during the 










6.3.2 Symptoms  
 
Scores from the hypoglycaemia symptom questionnaire were significantly higher during 
hypoglycaemia for autonomic, p = 0.004, η2   = .515, neuroglycopenic, p = 0.001, η2  = 
.584, and malaise symptoms, p  < 0.001, η2  = .706, compared to scores obtained during 
euglycaemia.   
 
6.3.3 Digit Symbol Substitution 
 
The mean score of the Digit Symbol Substitution test deteriorated from 99.4 (19.4) 
during euglycaemia to 91.7 (21.7) during hypoglycaemia, p = 0.009, η2 =.451. These 
findings establish that the hypoglycaemic intervention had the anticipated effects as 
demonstrated in similar hypoglycaemic clamp studies. 
 
6.3.4 Reaction time and accuracy 
 
The number of correct responses fell from 109.5 (2.8) during euglycaemia to 104.6 (4.8) 
during hypoglycaemia, p = 0.002, η2  = .558. The mean reaction time also increased 
significantly during hypoglycaemia (691.2 (136.3) milliseconds) compared to 104.6 (4.8) 
milliseconds during euglycaemia, p = 0.019, η2 = .382. The number of asterisks was 
grouped into eight categories (31-35, 36-40, 41-45, 51-55, 56-60, 61-65, 66-70) and the 
reaction times calculated and compared for each condition (euglycaemia versus 





































































































6.4.5. Diffuson model 
 
Responses from the first block of each session, short and long outlier RTs in all blocks, 
and the first response in each block were eliminated from data analyses. RT cutoffs used 
were a lower cutoff of 250 ms and an upper cutoff of 3000 ms. Summaries of the basic 
data are shown in Figure 6.2 The top panels show the proportion of ‘large’ responses as 
a function of the eight conditions (8 groups of numbers of asterisks) for the 
experimental (hypoglycaemic) and control (euglycaemic) conditions. The bottom panels 
show mean RT for ‘large’ and ‘small’ responses as a function of the number of asterisks 
for the two conditions. As the figures show, the probability of a ‘large’ response varies 
across the eight conditions from near 1 for stimuli with large numbers of asterisks to 
near 0 for stimuli with small numbers of asterisks. RT becomes longer for the 
conditions with intermediate numbers of asterisks. 
 
Diffusion model fits. The diffusion model was fit to the data from each subject for each 
session. To display the fits, we computed the average over subjects for the quantile RTs 
and the response proportions for the data and, for the model, we generated predictions 
from the parameter values averaged over subjects. 
We used quantile probability functions to display the quality of the fit of the model to 
the data. For each plot, the 0.1, 0.3, 0.5 (median), 0.7, and 0.9 quantiles of the RT 
distribution for each of the eight experimental conditions are plotted as a function of 
response proportion.  
The only significant difference among model parameters as a function of the 
experimental manipulation is a reduction of mean drift rate from 0.290 to 0.211, p 































Table 6.2: The parameters of the model are: a=boundary separation, z is the starting point, Ter=duration of 
nondecision components of processing, h=standard deviation in drift across trials, sz=range of the distribution of 
starting point (z) across trials, v1-v4 are drift rates for the groupings shown in Figure 1, po=proportion of contaminants, 
vc=drift criterion (a value added to drift rates for “small” responses and subtracted from drift rates for “large” 
responses), and st=range of the distribution of nondecision times across trials. x
2 is the goodness of fit index. 
 
 
Condition Statistic a Ter 
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η sz v1 v2 v3 v4 po st 
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0.046 0.060 0.070 0.037 0.122 0.095 0.056 0.027 0.002 0.028 0.036 0.019 20. 
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mean 
data 















The results from this study show a powerful dissociation in terms of the diffusion 
model analysis. The model shows clearly that hypoglycaemia reduces drift rates by .08 
out of .29 (with an even larger effect on the most accuracy conditions; the mean of v1 
and v2 is reduced from 0.39 to 0.27). This indicates that hypoglycaemia affects central 
processing and not the quantity of evidence required to make a decision (boundary 
separation, a), or peripheral and motor processes (nondecision component, Ter). This 
numerosity task was chosen because it is a reasonable control task in that there are not 
perceptual limitations (such as brief presentation time), no memory limitations as there 
might be in a memory task, and no limitations dependent on language knowledge. Drift 
rate in this task represents the estimate of numerosity of the stimulus derived from the 
array of asterisks. The variability in this estimate comes from the random arrangement 
of asterisks in the array. As far as we are aware, this is the first study to dissect the 
effects of hypoglycaemia in this way. The data now afford the opportunity to compare 
and contrast, precisely, the cerebral effects of hypoglycaemia and other factors. 
Acute hypoglycaemia is a common side effect in people with insulin-treated diabetes, 
due to the non-physiological doses of insulin that are used in standard insulin regimens 
often leading to a mismatch between blood glucose and plasma insulin concentrations. 
The frequency of hypoglycaemia has been examined most extensively in people with 
type 1 diabetes, in whom mild (self-treated) hypoglycaemia occurs on average around 
twice weekly [28,29]. These episodes of acute hypoglycaemia lead to an impairment of 
mental performance and thus have important implications for work performance and 
the ability to carry out everyday tasks such as driving.   However tasks such as driving 





information processing, attention and others. Hence, the precise neurobiological and 
cognitive bases of the decrement observed during testing remained poorly understood. 
As outlined in the introduction, prior research had more crudely indicated that visual 
and auditory processing showed decrements during hypoglycaemia and that peripheral 
nerve conduction was not affected (10-12). However, the dissection of specific decision 
making parameters that were studied here was not possible.  
The dissociation of model parameters in the present study contrasts nicely with the 
effects of aging on processing in this task. Ratcliff, Thapar, and McKoon (30); Ratcliff, 
(31) observed that aging affected boundary separation and the nondecision component, 
but not drift rate. In contrast to aging, Ratcliff and Van Dongen (32) found that sleep 
deprivation affected drift rate to about the same degree as hypoglycemia, but also had a 
small effect on boundary separation. Further work is required to ascertain the potential 
additive effects of sleep deprivation and hypoglycaemia.  
Strengths of the present study include the use of a powerful intervention in a within-
subjects design. The task itself has a number of advantages for the beginning of an 
investigation. First, it has no perceptual or memory demands, the array is presented until 
the subject responds. In this sense it provides a useful baseline for other more cognitive 
or perceptual tasks. Second, by varying the number of asterisks, performance varies 
from near ceiling (100% accurate) to near floor (50% accurate). Third, the task has been 
successfully modelled in a number of domains such as in studies examining the effects 
of development, aging, sleep deprivation, and IQ on performance. It is a limitation of 










In conclusion, the present study is the first to locate the precise processing deficit that is 
associated with hypoglycaemia. This new information can lead in at least two directions, 
which are basic and applied. First, further work should bring together knowledge of the 
precise neurobiological effects of hypoglycaemia to link it with what we have now found 
to be the precise cognitive processing effects. This can help to reveal the neurobiology 
of thought processes at a mechanistic level that is rarely achieved. Second, 
understanding the cognitive processing parameters affected by hypoglycaemia and other 
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An evaluation of methods of assessing impaired 








































Hypoglycaemia is a common side-effect of insulin treatment in type 1 diabetes and is 
detected by the subjective recognition of typical autonomic symptoms such as sweating, 
tremor and hunger, and neuroglycopenic symptoms such as drowsiness and difficulty in 
concentrating [1]. The early perception of these warning symptoms is fundamental to 
promote self-treatment and prevent progression to severe hypoglycaemia (SH) and the 
recognition of the onset of these premonitory symptoms constitutes “awareness” of 
hypoglycaemia [2-4].  However with increasing duration of insulin therapy, many people 
with type 1 diabetes experience a significant change in their awareness of hypoglycaemia 
associated with either a reduction in symptom intensity or a change in symptom profile 
[4-7]. Neuroglycopenic symptoms such as confusion, drowsiness and an inability to 
concentrate become predominant, while autonomic symptoms diminish in prevalence 
and intensity. This leads to the development of   “impaired awareness of hypoglycaemia”, 
which is recognised to be an acquired syndrome associated with cerebral adaptation 
resulting from recurrent exposure to low blood glucose levels [5]. Impaired awareness of 
hypoglycaemia (IAH) is a prominent risk factor for SH and is associated with a three to 
six-fold increase in their frequency [8, 9].  
 
This clinical syndrome varies in severity and is associated with significant morbidity, 
while also influencing medical fitness to drive. Accurate identification of affected 
individuals with impaired awareness of hypoglycaemia is therefore important to allow 
modification of their glycaemic targets and if necessary adjust insulin therapy to 
minimise the risk of severe hypoglycaemia. At present, three methods have been 





has examined the relationship between one of these methods using hypoglycaemia 
questionnaire, prospective blood glucose monitoring and glucose clamp studies to 
induce hypoglycaemia in assessing hypoglycaemia awareness [11]. However, the three 
methods currently available for clinical use have not been compared.  
The present study was performed in a randomly selected cohort of people with type 1 
diabetes to assess the concordance between these methods ascertaining the prevalence 




The study protocol was approved by the Lothian medical research ethics committee, 




A group of 140 adults with type 1 diabetes (defined by having two or more of the 
following characteristics: onset when aged less than 40 years, lean body habitus at time 
of diagnosis, commencement of insulin therapy at time of diagnosis or a history of 
diabetic ketoacidosis) who had attended the outpatient diabetes clinic over a period of 
12 months, were selected at random. Eighty subjects completed the monitoring period 
(which will be discussed in full in section 7.2.2), 55 male; HbA1c mean (SD) 8.1% (1.4); 
age median (IQR) 47.5 (35.5-56.3); duration of diabetes, median (IQR), 20 years (9-31). 
Participants had to have had type 1 diabetes of more than two years duration and be 
over 16 years of age.  Subjects were excluded if they were pregnant, had renal failure or 





about the presence of microvascular complications was obtained from their medical 
records.   
 
7.2.2 Methods of assessing awareness of hypoglycaemia 
 
The Gold method [8] poses the question: “do you know when your hypos are 
commencing?” The respondent then completes a 7-point Likert scale with 1 
representing “always aware” and 7 representing “never aware”. A score of 4 or more 
implies impaired awareness of hypoglycaemia. 
The Clarke method [9] comprises eight questions characterising the participant’s 
exposure to episodes of moderate and severe hypoglycaemia. It also examines the 
glycaemic threshold for, and symptomatic responses to, hypoglycaemia. A score of 4 or 
more implies impaired awareness of hypoglycaemia. 
The Pedersen-Bjergaard method [10] requires the patient to respond to the question: “do 
you have symptoms when you have a hypo?” requiring the selection of one response 
from “always”, “sometimes” or “never”.   Only patients who answer “always” are 
considered to have normal symptomatic awareness of hypoglycaemia, the others are 
designated as having impaired or absent awareness.   
Awareness of hypoglycaemia was assessed using each of the three methods (Gold, Clark9 
& Pedersen-Bjergaard). All participants completed a questionnaire for each method in the 
presence of a member of the research team who could, if necessary, explain the 
terminology used and ensure the complete comprehension of the questions by the 
participants.  Clinical information was obtained on the insulin regimen being used and 
on concurrent medications.  The participants were then asked to perform capillary 





testing before meals and at bedtime and the results were recorded in a diary. When any 
blood glucose value was recorded as being less than 3 mmol/L, the subjects were asked 
to complete a validated symptom questionnaire (the Edinburgh Hypoglycaemia Score) 
to document the nature and the intensity of the hypoglycaemic symptoms that were 
experienced at that time [1]. Information was also documented as to whether the onset 
of the episode of hypoglycaemia was recognised by the participant or by an independent 
observer and the treatment used. The completed diaries and information sheets were 
returned to the investigators at the conclusion of the four-week monitoring period.  
 
7.2.3 Statistical analyses 
 
All analyses were performed using SPSS version 12.0 for Windows. The Kolmogorow-
Smirnov test was applied to check the normality of the variables, depending on which, 
differences between groups were analysed using either the two-sample t test or Mann-
Whitney-U test. To assess the linear relationship between two variables a Spearman 
correlation coefficient was calculated. Differences between the groups were analysed 
using χ2.  A p value < 0.05 was considered to be significant. All results are reported as 
mean (SD) unless otherwise stated.  
 
7.3 Results 
Of the 140 participants recruited, 80 completed the blood glucose-monitoring period 
for one month and returned the results. Those who completed the study (n = 80) were 
significantly older than those who did not (n = 60), (47.6 (12.7) vs. 41.1 (12.6) years, p = 
0.04).  No differences in duration of diabetes (p = 0.7) or in glycaemic control (p = 





7.3.1 Prevalence of impaired awareness of hypoglycaemia 
The prevalence of impaired awareness of hypoglycaemia as identified by the Gold, Clarke 
and Pedersen-Bjergaard methods were 24%, 26% and 62.5% respectively (Table 7. 1), 
(Figure 7.1). A strong association, using Spearman’s test was found between the Gold 
and Clarke methods for identifying impaired awareness (rs = 0.868, p = 0.001).  
Those with IAH identified by the Gold method (p = 0.01) and the Clarke method (p = 
0.004) were significantly older than those patients who were designated as having had 
normal awareness when using either of these two methods (Table 1). No age difference 
was observed between the two groups of aware and IAH patients applying the Pedersen-
Bjergaard method (p = 0.10). The duration of diabetes was significantly longer in the 
IAH group of patients with all three methods but no statistical difference was observed 








Table 7.1: Clinical characteristics of participants with type 1 diabetes by methods of assessment of awareness of hypoglycaemia 
 
      
Method of 
evaluation      
Gold method8  
 
Clarke method9 Pedersen-Bjergaard method10
Awareness 
 
NAH IAH p NAH IAH p NAH IAH p 
Number (%) 
 
























































68.4 % 85.7 % 0.51 77.6% 95% 0.09 75 % 86.7 % 0.85 
HbA1c (%) 
 








Figure 7.1: Frequency of awareness of hypoglycaemia by methods of assessment of 
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7.3.2 Frequency of biochemical hypoglycaemia 
The frequency of recorded episodes of biochemical hypoglycaemia is shown in Table 7.2. 
The patients designated as having IAH using the Gold and Clarke methods reported a 
significantly higher number of episodes of biochemical hypoglycaemia over the four-week 
monitoring period than those patients considered to have normal awareness of 
hypoglycaemia. No statistical difference in mean number of hypoglycaemia episodes was 
observed between the two sub-groups using the Pedersen-Bjergaard method (p = 0.06). The 
mean number of home blood glucose measurements between 2.5-2.99 mmol/L and <2.5 
mmol/L differed significantly between the Gold and Clarke subgroups (IAH and normal 
awareness) but differences in the frequency of hypoglycaemia were not apparent using the 
Pedersen-Bjergaard method (p = 0.11). During the four-week period of prospective blood 
glucose monitoring, the reported intensity of autonomic symptoms was lower during 
episodes of biochemical hypoglycaemia in those who had IAH as identified using the 
Clarke and Gold methods, compared to patients designated as having normal awareness. No 
symptomatic differences were observed between the groups identified using the Pedersen-
Bjergaard method (p = 0.22). No statistical differences between groups with IAH and 
normal awareness were observed in the recorded intensity of neuroglycopenic symptoms 
during episodes of hypoglycaemia with any of the methods evaluated. 
In the present study, the mean incidence of severe hypoglycaemia reported to have 
occurred during the preceding year was statistically different between those identified as 








Table 7.2: The frequency of episodes of biochemical hypoglycaemia over  
the 4 week period and recollected total number of episodes of severe  
hypoglycaemia (SH) during the previous year.  
 
  Method of 







NAH IAH  p NAH IAH p NAH IAH p 
From record 
sheets (%) 




























































0 (0) 0.55 
 




































% of episodes 
recognised by 
participant 
85% 50% 0.014 90% 47.6% 0.013 92% 62% 0.013 
% of episodes 
identified from 
meter  
13% 48% 0.26 9% 50.0% 0.261 8% 36% 0.395 
% of episodes 
recognised by 
someone else 






























Impaired awareness of hypoglycaemia is a frequent problem in people with type 1 diabetes, 
becoming more common with increasing duration of diabetes [5,7,13] and being associated 
with strict glycaemic control [4,7]. It is not an “all or nothing” phenomenon and usually 
develops gradually over months to years. No clear consensus exists for the definition of 
impaired awareness of hypoglycaemia, but clinical assessment should be based on the 
everyday experiences of people treated with insulin, and not on observations carried out in 
the artificial setting of experimentally-induced hypoglycaemia in a laboratory, which does 
not simulate normal experience. Symptom generation differs during the induction of 
hypoglycaemia using a clamp technique than hypoglycaemia that occurs during waking 
hours in a community setting. Furthermore, symptoms can be modified and diminished in 
intensity in certain circumstances but these isolated events do not constitute impaired 
awareness of hypoglycaemia, so the diagnosis of the established syndrome should not be 
made on this basis.  
Three methods are currently available to assess symptomatic awareness of hypoglycaemia.  
In the present study these methodologies have been evaluated for their sensitivity in 
identifying impaired awareness of hypoglycaemia and their mutual concordance. In a 
present cohort of randomly selected adults with type 1 diabetes, equivalent prevalence of 
impaired awareness (24% and 26%) were obtained with two of the methods (Gold and 
Clarke) but differed considerably from the prevalence observed using the method of 
Pedersen-Bjergaard (62.5%). Previous population surveys have indicated that impaired 
awareness of hypoglycaemia affects approximately one-quarter of unselected adult 
populations with type 1 diabetes which is consistent with the estimates using the Gold and 





In the present study, differences were also apparent between the methods with respect to 
patients who were identified as being at high risk of impaired awareness. Applying the 
Clarke and Gold methods, the patients that the methods identified as having IAH were 
older, had a longer duration of diabetes and had a history of experiencing more episodes of 
severe hypoglycaemia during the year preceding the study, which is consistent with the 
recognised features of this syndrome [8, 9, 13].  The frequency of mild (and asymptomatic) 
hypoglycaemia episodes was also significantly higher in the groups with impaired awareness 
identified by the methods of Gold and Clarke and these patients had significantly lower 
autonomic and higher neuroglycopenic symptom scores during hypoglycaemia compared 
to those with intact awareness, which are recognised features of this syndrome. The 
difference in neuroglycopenia scores between these two groups failed to reach statistical 
significance, but this symptom profile is typical of patients with impaired awareness. The 
absence of a statistical difference in relation to the neuroglycopenia symptom scores 
between the two sub-groups reflects the arbitrary cut-off value of blood glucose of less 
than 3.0 mmol/L that was chosen for the subjects to record their responses to 
hypoglycaemia. This coincides approximately with the glycaemic threshold (3.2 – 2.8 
mmol/L) for the generation of the symptomatic response to hypoglycaemia whereby 
deprivation of glucose causes a rapid deterioration in cognitive function with the 
subsequent generation of neuroglycopenic symptoms [15].  The Pedersen-Bjergaard method 
not only recorded a much higher prevalence of IAH but was less discriminating and 
identified only those patients who had a long duration of diabetes and a history of previous 
SH as characteristics relevant to those who had impaired symptomatic awareness. 
The Gold and Clarke methods both validated the accuracy of their evaluation questionnaires 
by using a prospective period of home blood glucose monitoring (varying from 6-12 





perceive the onset of symptoms to hypoglycaemia were recorded and compared with the 
assessment based on the questionnaire. By contrast, the much simpler Pedersen-Bjergaard 
method was evaluated by administering their simple questionnaire to a group of individuals 
with type 1 diabetes who were then followed prospectively to record their prevalence of 
SH. Those designated as having “impaired awareness” and “unawareness” did have an 
overall higher frequency of severe hypoglycaemia compared to the group with “normal 
awareness”, and this was advocated as justification of this method of assessment of 
hypoglycaemia awareness status.  
The present study also demonstrated a strong correlation between the Clarke and Gold 
methods (rs = 0.868, p = 0.001). The Clarke method has also been externally validated by a 
different group of investigators, who found that Clarke’s self-report questionnaire achieved 
reasonable agreement with the autonomic symptom threshold during experimental 
hypoglycaemia (sensitivity 66.7%, specificity 85.7%), although prospectively recorded home 
blood glucose readings were not related to the hypoglycaemic clamp findings [11]. However 
the authors conceded that these disparate findings result from using an arbitrary cut-off 
blood glucose of <3.9mmol/L for the recognition of hypoglycaemic symptoms and 
suggested that this could be rectified by applying a value of <3.0mmol/L, as was applied in 
the present study.  
When methods that utilise questionnaires are used to ascertain awareness of 
hypoglycaemia, some overlap will occur and no currently available method can be 
considered to totally reliable. However, the Pedersen-Bjergaard method to identify patients 
with impaired awareness of hypoglycaemia represents too simplified an approach to a 
complex clinical condition and appears to be insensitive and insufficiently discriminating, 
so over-estimating the prevalence of this clinical syndrome. It cannot therefore be 





In conclusion this present evaluation of methods of assessing symptomatic awareness 
demonstrates that, for both clinical and research use, the Clarke and Gold methods should 
be used preferentially, either separately or in combination, to identify people with type 1 
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Hypoglycaemia is a common and disruptive side effect of insulin treatment for type 1 
diabetes. Hypoglycaemia may be “mild” where the patient can identify falling glucose levels 
and take appropriate corrective action ( ingestion of carbohydrate) or severe when glucose 
levels fall to a level where cognitive impairment prevents them from being able to treat 
themselves and they require third party assistance. Subjective recognition of the symptoms 
of hypoglycaemia is fundamental to enable effective self-management of hypoglycaemia 
and prevent progression to severe hypoglycaemia (SH)[1,2]. The ability to perceive the 
onset of these symptoms is fundamental to normal “awareness” of hypoglycaemia.  
Previous studies have suggested that impairment of awareness is associated with a three to 
six-fold increase in the frequency of episodes of severe hypoglycaemia [2-4].  
Antecedent hypoglycaemia has been implicated in the pathogenesis of impaired awareness 
of hypoglycaemia (IAH) by blunting symptomatic and hormonal responses to subsequent 
hypoglycaemia [5,6]. However, once this syndrome has developed it is unclear whether it is 
associated with a substantial increase in the frequency of mild biochemical hypoglycaemia. 
A 12 month prospective study, which compared 31 patients with type 1 diabetes who had 
normal awareness with 29 who had IAH, observed no difference in the total number of 
episodes of mild hypoglycaemia between the two groups [4].  
Continuous glucose monitoring (CGM) provides near continuous information about 
interstitial tissue glucose levels, allowing an examination of exposure to low blood glucose 
concentrations over several days. This raises two questions. Firstly, are subjects with type 1 
diabetes that have impaired awareness of hypoglycaemia exposed to more asymptomatic 
biochemical hypoglycaemia? Secondly, if so, is a standard monitoring period of 4-5 days 
using CGM sufficient to identify those with a higher rate of biochemical hypoglycaemia 





8.2  Methods 
Each participant was provided with similar capillary glucose testing devices (Medisense G 
glucose meter, Abbott Laboratories, Abbott Park, IL, USA) and were requested to perform 
one four-point blood glucose profile daily, (three measurements before meals and one at 
bedtime) in a 24 hour period, once a week for the duration of the study (BGM data). They 
were also asked to record all episodes of self-reported hypoglycaemia (a capillary blood 
glucose reading <3.5mmol/l, with or without symptoms) and severe hypoglycaemia (SH), 
(any event requiring assistance for recovery), during this time. Subjects were contacted 
monthly by members of the research team to collect both the BGM and self-reported 
hypoglycaemia data. After screening, participants underwent CGM, (Medtronic CGMS, 
Medtronic, Minneapolis, MN, USA) for at least 96 hours (mean 5 days). Monitoring 
devices were calibrated five times per day.  
 
8.2.1 Subjects 
The data analysed had been collected as part of the UK Hypoglycaemia Group Study [7]. A 
group of 95 adults with type 1 diabetes as defined by WHO criteria [8], were studied 
prospectively over a one-year period, and their characteristics are shown in table 8.1.  
Awareness of hypoglycaemia was characterised at screening using the method of  Gold et 
al [4], a validated scoring system (as discussed in Chapter 7) in which subjects are asked to 
respond to the question: “do you know when your hypos are commencing?” on a 7-point 
Likert scale, with 1 representing “always aware” and 7 representing “never aware”.  A score 
of 4 or more has been shown to be consistent with diminished symptomatic responses to 
hypoglycaemia (impaired awareness of hypoglycaemia) [4,9], and this method has been 
shown in Chapter 7 to have close concordance[9] with the method described by Clarke et 





severe systemic disease or malignancy, a history of seizures unrelated to hypoglycaemia, or 
inability to give informed consent. The study had medical ethics committee approval, and 
written informed consent was obtained from all participants.  
 
8.2.2 Analysis of CGM 
To avoid artefacts such as sensor failure being falsely identified as hypoglycaemia, two 
observers independently analysed each CGM trace (software version 1.7a), and a third 
observer reconciled any discrepancies. Data that did not meet stringent validity criteria 
were excluded (mean absolute error (MAE) < 28%, at least 3 calibrations / 24 hrs and data 
located between two paired calibration points). Total duration of valid data was calculated 
and periods of low interstitial glucose (LIG) were stratified into episodes <3 mmol/l 
(LIG3.0) and those <2.2 mmol/l (LIG2.2). LIG was defined as an episode of sensor glucose 
below the threshold value (2.2 or 3.0 mmol/l respectively) for at least 20 min and the 
episode was completed once the glucose remained above the respective threshold value for 
a further 20 min [8]. We selected these glucose levels on the basis of previous observations 
that cognitive function deteriorates at around an arterialised blood glucose level of 3.0 
mmol/l [10,11] and because 2.2 mmol/l, which is the limit of detection of a low interstitial 
glucose using a CGM device, has been shown to correlate with clinical hypoglycaemia[12]. 
 
 
8.2.3 Biochemical analysis 
HbA1c was DCCT aligned and measured by ion exchange high performance liquid 
chromatography (Tosch Automated Glycohaemoglobin Analyser). C-peptide was measured 





Angiotensin-Converting Enzyme (ACE) was measured by a rapid spectrophotometric 
method (Sigma Diagnostics, St Louis, MO, USA).  
 
8.2.4 Statistical analysis 
Initial comparisons between groups (NAH versus IAH) for continuous variables were 
performed using the two-sample t test or Mann-Whitney-U test where necessary. For 
categorical variables differences in proportions between the groups were compared using 
the Chi-squared test with continuity correction or Fisher’s exact test when necessary. Many 
individuals experienced no episodes of hypoglycaemia (either self-reported or biochemical) 
during monitoring and relatively few experienced multiple episodes. Thus in order to 
compare rates of hypoglycaemia between groups a negative binomial model was fitted to 
the data as this took into account both the exposure time and the excess of individuals who 
had no events during monitoring periods [13]. All analyses were performed using SPSS 
version 14.0 for Windows and STATA version 8. A p-value < 0.05 was considered to be 
significant and no adjustments were made for multiple comparisons [14].  
  
8.3 Results 
Data were analysed from 95 subjects who completed the study and baseline characteristics 
are shown in Table 8.1. Those identified as having IAH (n = 21) had a significantly longer 
duration of diabetes compared to those with normal awareness of hypoglycaemia, (median 
(IQR) 34(16-44) vs. 4 (2-27) yrs; p< 0.001) but no significant differences were observed 
between the groups with regard to age (p= 0.12), serum ACE levels (p=0.28), gender (p = 
0.07) or glycaemic control as measured by HbA1c (p= 0.08) (Table 6.1). Median (IQR) 






8.3.1 Frequency of Severe Hypoglycaemia 
Over the course of the study, patients with IAH had a 3-fold higher incidence of SH 
(requiring third party assistance) compared to those with NAH (incidence rate ratio (IRR): 
3.37, 95% CI: 1.3 to 8.7; p = 0.01), (Table 8.2, Figure 8.1). 
 
8.3.2 Frequency of hypoglycaemia on weekly capillary blood glucose 
monitoring 
Subjects with IAH recorded a 1.6 fold higher rate of biochemical hypoglycaemia (capillary 
glucose of < 3.5 mmol/l on weekly HBGM) than those patients with NAH (IRR: 1.63 



















Table 8.1: Clinical characteristics of participants with type 1 diabetes  















Age(years) 47.1 (13.4) 52.2 (12.1) 0.12 
BMI (kg/m2) 26.8 (4.9) 27.9 (4.4) 0.33 
Gender (%male) 68.9 47.6 0.07 
Duration of 
diabetes (years) 
14.4 (15.1) 30.6 (16.9) < 0.001 
 
Daily insulin dose 
(units) 
50.4 (25.8) 47.1 (22.7) 0.60 
HbA1c (%) 7.4 (1.0) 7.9 (0.6) 0.08 
Fasting C-peptide 
(pmol/l) 
0.32 (0.3) 0.25 (0.3) 0.42 





Table 8.2: Comparison of hypoglycaemia between individuals with type 1 diabetes 













0.82 (0.86) 1.29 (1.01) 0.02 
Daytime CGM Lig 
3.0 (mean) 
1.43 (0-4.22) 3.47 (0-6.9) 0.12 
Daytime CGM Lig 
3.0 (duration/mins) 
58 (40-90) 74 (37-107) 0.54 
Nighttime CGM Lig 
3.0 (mean) 
1.18 (0-3.5) 2.33 (0-3.57) 0.26 
Nighttime CGM Lig 
3.0 (duration/mins) 
110 (80-242) 79 (58-219) 0.17 
Daytime CGM Lig 
2.2 (mean) 
0 (0-1.52) 1.16 (0-3.1) 0.26 
Daytime CGM Lig 
2.2 (duration/mins) 
48 (30-100) 80 (38-135) 0.74 
Nighttime CGM Lig 
2.2 (mean) 
0 (0-1.75) 1.17 (0-148) 0.96 
Nighttime CGM Lig 
2.2 (duration/mins) 












Figure 8.1: Comparison of monthly rates of severe hypoglycaemia (self-
reported) between subjects with Normal Awareness of Hypoglycaemia 

































Figure 8.2: Comparison of monthly rates of biochemical hypoglycaemia 
between subjects with Normal Awareness of Hypoglycaemia (NAH) and 


















8.3.3 Frequency of patient reported hypoglycaemia 
No differences were observed between NAH and IAH subjects in the rate of patient 
reported symptomatic hypoglycaemia (NAH vs. IAH 2.99(4.07) vs. 2.64(2.83) episodes / 
week; p=0.7). Rates of hypoglycaemia across groups were consistent across the duration of 
the study (between 2.4 and 3.5 episodes / pt / month).   
 
8.3.4 CGM data 
All patients completed at least 96 hours of CGM data. Mean (SD) valid time was 4.9 (0.1) 
days/subject. 
 
8.3.4 Frequency and duration of hypoglycaemia on CGM 
No significant differences in frequency of biochemical hypoglycaemia measured as either 
LIG3.0 or LIG2.2 were observed [IRR for LIG3.0: 1.37 (95% CI: 0.94 to 2.00); p = 0.10; IRR 
for LIG2.2: 1.26 (95% CI: 0.71 to 2.23); p = 0.44]. No difference was observed in the 
median duration of each episode of hypoglycaemia between NAH and IAH (86 (53 to 145) 
vs. 79 (38 to 121) mins / episode; p= 0.37 for LIG3.0) or the percentage of total valid time 
with the sensor glucose <3.0mmol (3.9 vs. 4.8%; p= 0.59). 
When divided into day-time (08:00 – 24:00) and night-time ( 00:00 – 08:00) no difference 
was found between NAH or IAH either in the number of episodes of LIG3.0 ( day-time:  
1.43 (0-4.22) vs. 3.47(0-6.98) episodes /week; p=0.12; night-time: 1.18(0-3.5 vs. 2.33(0-3.6) 
episodes/week; p=0.26) or in the duration of time spent below a sensor glucose of 3.0 
mmol/l (day-time: 58 (40-90)  vs. 74(37-110) mins / episode) p= 0.54  ; night-time: 110(80-






8.3.5 Sensor glucose during symptomatic hypoglycaemia 
90 episodes of patient reported hypoglycaemia (74 in IAH patients) were reported for 
which there was simultaneous valid CGM data. Mean capillary glucose during patient 
reported hypoglycaemia was lower in IAH than NAH (2.8(0.5) vs. 2.4(0.5) mmol/l; p= 
0.005) although there was no difference in nadir sensor glucose (lowest sensor glucose 
within 2 hours of the reported time of hypoglycaemia). Approximately 10% of episodes of 
LIG were associated with symptomatic hypoglycaemia. However, between 80 and 90% of 




In this prospective observational study of unselected patients from 6 different centres in 
the UK, patients with type 1 diabetes with impaired awareness of hypoglycaemia (IAH) 
experienced a three-fold higher rate of severe hypoglycaemia, and a 1.6 fold higher rate of 
biochemical hypoglycaemia as measured by weekly 4-point home glucose monitoring 
compared to patients with normal hypoglycaemia awareness. However, no significant 
differences in biochemical hypoglycaemia (low interstitial glucose), measured using CGM, 
were detected between the two groups. 
Patients with IAH had a longer duration of diabetes and a higher risk of developing severe 
hypoglycaemia than those with normal awareness, consistent with previous reports 
[3,4,15,16].. The prevalence of IAH in the present study (22.1%) was also comparable to 
another recent estimate [17] confirming that the present study population was. typical of an 
unselected cohort of adults with type 1 diabetes. The majority of the participants in the 





education on diet and insulin dose adjustment such as the Dose Adjustment For Normal 
Eating (DAFNE) programme, which can reduce the frequency of severe 
hypoglycaemia[18].  
In the present study, we quantified the frequency of biochemical hypoglycaemia using two 
separate techniques. Although a higher frequency of biochemical hypoglycaemia was 
observed in those with IAH using weekly four point capillary glucose monitoring (BGM), 
no differences either in frequency or duration of LIG were observed with five days of 
CGM.  The disparate results obtained between these two methods were unexpected and 
contrast to those reported by Kubiack et al [19] in which a two-fold higher frequency of 
biochemical hypoglycaemia (assessed using CGM) was reported in patients with IAH.  
However, various methodological differences between the two studies may explain these 
seemingly contrary findings. The present study examined a larger number of patients, in 
whom hypoglycaemia awareness was determined using an established scoring system, and 
in contrast to the study by Kubiak et al[19], mean HbA1c was similar between the patients 
with and without IAH.  In addition, our study is more representative of everyday life as 
patients were studied in their home environment rather than in a hospital setting[19]. 
Kubiak et al used a higher glucose cut off of < 3.3mmol/l to define hypoglycaemia and did 
not exclude CGM data that did not satisfy validity criteria, so may have overestimated the 
incidence of hypoglycaemia. Data from the UK Hypoglycaemia Group Study[8,20] and 
from the DirecNet group [21]suggest that a sensor glucose level of 3.0mmol/l provides the 
optimum sensitivity and specificity for true hypoglycaemia. At higher glucose cut-off 
values, specificity is lost whereas at lower glucose levels sensitivity is affected.  
The 1.6 fold higher frequency of biochemical hypoglycaemia (with HBGM) in patients with 
IAH is  similar to that seen in a study by Geddes et al[9], (Study 7), who reported a 2.2 fold 





diabetes and IAH compared to those with NAH. HBGM has its limitations, in that the 
frequency of hypoglycaemia is dependent on the frequency and timing of testing. Many 
patients with IAH test their blood glucose more frequently than other patients, and times 
of testing may be biased towards times when hypoglycaemia is more likely. These problems 
were overcome in the present study by standardising the number of tests to a weekly 4-
point glucose profile at fixed times before meals and at bedtime. However, the trade off is 
that any inter-prandial, and in particular nocturnal, hypoglycaemic event may be missed and 
may therefore cause underestimation of the true difference between the groups. 
Participants were contacted by telephone on a monthly basis to ensure that data collection 
of the weekly capillary blood glucose data was complete and that all episodes of severe 
hypoglycaemia had been identified and recorded. 
While the data from recall of severe hypoglycaemia and analysis of BGM records are 
consistent with what was anticipated, the inability to detect any difference in hypoglycaemia 
with CGM between those with normal and impaired hypoglycaemia awareness was 
unexpected.  Several possible explanations can be considered. The most likely is 
insufficient duration of CGM to detect a difference in hypoglycaemia exposure between 
these groups, effectively introducing a type 2 error. Despite being encouraged to continue 
with their normal routine, participants might deliberately have avoided potential 
precipitants of hypoglycaemia such as physical exercise or ingestion of alcohol during the 
five days of CGM, measures that they would have been less likely to sustain over the longer 
period of the HBGM analysis. It is also possible that hypoglycaemia may be more common 
at the times designated for testing capillary glucose in those with IAH compared to people 
with normal awareness. Given the sample size, it is unlikely that we have missed a large 
difference in LIG rates between the two groups. This information is important, as in 





approval for only 72 hours. Our data would caution against using short duration of CGM 
to diagnose a patient with impaired awareness of hypoglycaemia as suggested by Kubiak et 
al[19].  
Another possibility is that while the frequencies of low interstitial glucose (LIG) may be 
similar, the episodes of biochemical hypoglycaemia may differ in terms of duration or 
depth. In patients with IAH, with reduced or absent symptomatic or counterregulatory 
responses, we may expect  episodes of hypoglycaemia to persist for longer before being 
recognised and treated and we would expect a greater proportion of time in the patients 
with IAH at the lower threshold of LIG2.2 compared to LIG3.0. However, the median 
duration of each episode or the total time spent with interstitial glucose either <3.0 mmol/l 
or <2.2 mmol/l did not differ between the groups. As the CGM system cannot record 
below 2.2mmol/l, it was not possible to determine what proportion of time might have 
been spent at very low glucose levels. 
Concern has been expressed about the accuracy of CGM, particularly at hypoglycaemic 
levels [22] because of the physiological delay between blood and interstitial glucose which 
may be exaggerated when blood glucose is falling rapidly[23]. In patients with type 1 
diabetes during experimental hypoglycaemia, CGM underestimates interstitial tissue glucose 
concentrations [24] and thus may overestimate the frequency of hypoglycaemia. Another 
problem when interpreting CGM traces is that if the sensor fails, the trace “flat-lines” 
which could be interpreted as persistent hypoglycaemia. We minimised the likelihood of 
this occurring by discarding any data that did not meet stringent accuracy criteria or were 
not obtained between two paired readings. In addition, traces were analysed by two 






80% of episodes of symptomatic hypoglycaemia were associated with sensor glucose 
<3.5mmol/l similar to previous reports[12]. However only 10% of episodes of LIG were 
associated with symptomatic hypoglycaemia and this was not different between those with 
IAH and NAH. This suggests low specificity of LIG to identify clinically relevant 
hypoglycaemia. The high proportion of LIG with no symptoms, even in those with NAH 
does raise concerns about the clinical relevance of these episodes and the validity of using 
them to diagnose IAH. 
The results of the present study would suggest that, despite exposure to a similar frequency 
and duration of biochemical hypoglycaemia, patients with IAH remain three times more 
susceptible to severe hypoglycaemia, and this may indicate a difference in their ability to 
self-treat in the presence of profound neuroglycopenia. Some studies have found that low 
serum ACE concentrations may predict a  lower risk of severe hypoglycaemia, despite a 
similar rate of biochemical hypoglycaemia [26-28] although this was not seen in other 
studies[29] or in our study. Patients with IAH have a reduced global brain glucose uptake 
during hypoglycaemia compared to those with NAH, with reduced uptake in the sub-
thalamic regions of the brain, which are known to be important in the generation of 
physiological responses to hypoglycaemia [30].  It is unclear whether these differences 
could explain why people with IAH are more susceptible to SH than those with normal 
awareness despite similar exposure to biochemical hypoglycaemia.  
In conclusion, while our study confirms the higher risks of severe (3-fold) and biochemical 
(1.6-fold) hypoglycaemia in patients with IAH, five days of continuous glucose monitoring 
is not sufficient to identify people with IAH. It also raises the possibility that patients with 
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In unselected populations of people with type 1 diabetes the estimated incidence of severe 
hypoglycaemia (requiring external help) ranges from 1.0 to > 3.0 episodes/patient/year [1-
4].  Subjective recognition of the symptoms of hypoglycaemia is fundamental to effective 
self-management to prevent progression to severe hypoglycaemia [5, 6].  However, with 
increasing duration of treatment with insulin many people with type 1 diabetes experience a 
change in their symptoms of hypoglycaemia [7-9], manifested as either a reduction in 
intensity or number, or a change in symptom profile, so that neuroglycopenic symptoms 
predominate, while autonomic symptoms are less prominent or absent.  
This diminished ability to perceive the onset of hypoglycaemia (impaired awareness of 
hypoglycaemia (IAH), is alleged to affect approximately 25% of people with type 1 diabetes 
[10,11].  This estimate was derived from small studies conducted in the 1980s and early 
1990s, which utilised a retrospective review of clinical histories.  However, validated 
methods of assessment, which have been developed subsequently, have not been applied to 
a large hospital clinic-based population.  In addition, as IAH is thought to be induced by 
recurrent exposure to hypoglycaemia, the introduction of new insulin analogues, the 
intensification of insulin regimens and improved methods of patient education may help to 
minimise exposure to hypoglycaemia and hence potentially decrease the prevalence of 
IAH.  The present study was therefore performed to ascertain this prevalence in a 
randomly selected cohort of people with type 1 diabetes using the method described by 
Gold et al [12]. 
 
9.2 Methods 
Adults with type 1 diabetes attending a diabetes outpatient clinic at the Royal Infirmary of 





for the survey.  Inclusion criteria consisted of type 1 diabetes of more than two years 
duration and being aged over 16 years.  Exclusion criteria were pregnancy, advanced renal 
failure or inability to understand or complete the questionnaire.  The local medical ethics 
committee approved the study, and informed consent was obtained from all participants. 
Each participant completed a general questionnaire to document baseline demographic 
characteristics and quantified the frequency of exposure to self-treated hypoglycaemia and 
episodes of severe hypoglycaemia (defined as requiring external assistance) during the 
preceding 12 months.  Retrospective recall of severe hypoglycaemia over a period of one 
year is a robust measure in people with type 1 diabetes [13].  An investigator was present to 
assist with clarification of the content of the questionnaire if required.  
Awareness of hypoglycaemia was assessed using the method described by Gold et al [12], 
which asks the question: “do you know when your hypos are commencing?” The 
respondent selects a number on a 7-point Likert scale with 1 representing “always aware” 
and 7 representing “never aware”. A score of 4 or more is designated as impaired 
awareness of hypoglycaemia. In addition to this subjects are asked if they have noticed a 
subjective alteration in their warning symptoms and their frequency of exposure to severe 
hypoglycaemia in the year preceding the study. Hypoglycaemia symptom scores were 
assessed using the Edinburgh Hypoglycaemia Scale [14]. 
 
9.2.1 Subjects 
The questionnaire was completed by 518 adults with type 1 diabetes (242 male; mean (SD) 
HbA1c 8.4 (1.4) %; median (inter quartile range, IQR) age, 39.0 (31-50) years; duration of 
diabetes, 16 (9-24) years. This group were using either insulin analogues (n=384; 74%), a 





8%).  A basal-bolus insulin regimen was used by 82.3% (n=426), with 17.7% (n = 92) on a 
twice-daily regimen of fixed insulin mixtures, such as 30% soluble, 70% isophane.  
 
9.2.2 Statistical analysis 
All analyses were performed using SPSS version 12.0 for Windows. Differences between 
groups were analyzed using either the two-sample t test or Mann-Whitney-U test. To assess 
the linear relationship between two variables a Spearman correlation coefficient was 
calculated. A p value < 0.05 was considered significant. All results are reported as mean 
(SD) unless otherwise stated.  
 
9.3 Results  
IAH was present in 19.5% (n = 101), (Figure 9.1). Compared to people with normal 
awareness of hypoglycaemia, those with IAH were significantly older (p < 0.001) and had 
diabetes for longer (p < 0.001) (Table 9.1). The rate of severe hypoglycaemia in the 
preceding year was six-fold higher in those with IAH compared to those with normal 
awareness (p < 0.001), (Figure 9.1). The prevalence of SH in the preceding year was 20.1% 
in the group with normal awareness and 50.5% in those with IAH (Figure 9.1). The 
reported intensity of autonomic symptoms was lower during episodes of self-treated 
hypoglycaemia in those with impaired awareness compared to those with normal awareness 
(p = 0.004). No statistical differences were observed between the groups (IAH versus 
normal awareness) in the intensity of neuroglycopenic symptoms (p = 0.44). No 
differences were also observed with respect to glycaemic control (HbA1c 8.3 (1.4) % vs. 






Figure 9.1: Prevalence and incidence of severe hypoglycaemia (SH) in the year 
preceding the survey of 518 adults with type 1 diabetes, with, and without, impaired 










































Table 9.1: Clinical characteristics of participants with type 1 diabetes by awareness 
of hypoglycaemia 
Awareness Normal Impaired  P 
 
Number (%) 417 (80.5%) 101 (19.5%) - 
 




14 (8-22)  
 
23 (14-32) < 0.001 
HbA1c (%) 8.3 (1.4) 8.4 (1.4) 0.92 
 
Incidence of SH in preceding year 0.38 (1.0) 2.36 (4.8) < 0.001 
 
Autonomic symptoms 2.94 (1.1) 2.05 (1.2) 0.004 
 
Neuroglycopenic symptoms 2.35 (1.0) 2.40 (1.1) 0.44 
 



























IAH and duration of diabetes (rs = 0.21, p = < 0.001) and between IAH and rate of SH (rs = 




The present survey, using a validated method of assessment, has demonstrated a prevalence 
of IAH of approximately 20% in an unselected adult population with type 1 diabetes. This 
is similar to previous estimates made 15-20 years ago that were derived on clinical history 
from hospital and community-based populations [9, 10, 15, 16]. Those with IAH were 
older, had a longer duration of diabetes, and had a six-fold higher frequency of episodes of 
severe hypoglycaemia and a lower intensity of autonomic symptoms during hypoglycaemia, 
all of which are consistent with recognised characteristics of this acquired syndrome [9, 12, 
and 16]. Thus the method of Gold et al appears to be sufficiently discriminating in the 
identification of those with IAH.  
A potential limitation in defining the prevalence of IAH with precision is that this is not an 
“all or nothing” phenomenon. Several studies of people with [19], and without, type 1 
diabetes [20-22] have suggested that exposure to antecedent hypoglycaemia can shift the 
glycaemic thresholds for cognitive dysfunction, symptom generation and counterregulatory 
hormonal secretion to lower blood glucose levels, while strict avoidance of hypoglycaemia 
can restore normal responses [23].  
Views differ regarding the most appropriate methods and situations in which evaluation of 
the awareness of hypoglycaemia should be undertaken, ranging from the use of 
questionnaires, identification of symptom generation during experimental hypoglycaemia 





opinion as stated previously, IAH should be evaluated within the everyday experience of 
people treated with insulin, and not from observations carried out in the artificial setting of 
controlled hypoglycaemia in the laboratory. CGMS as demonstrated in Chapter 8 has no 
useful contributory role in identifying those with IAH.   The other questionnaire method 
for assessing awareness of hypoglycaemia is that of Clarke et al [25] , which has been 
externally validated by a different group of investigators, who examined the relationship 
between the hypoglycaemia questionnaire, prospective blood glucose monitoring and 
glucose clamp studies to assess hypoglycaemia awareness [18].   As demonstrated in study 3 
(Chapter 7) the Clarke [25] and Gold [12] methods have been proven to be sufficiently 
sensitive in identifying impaired awareness of hypoglycaemia and for their mutual 
concordance [17]. A strong correlation was demonstrated between the two methods (rest = 
0.868, p = 0.001) in identifying people with IAH. Those identified by both methods as 
having IAH were older, had a longer duration of diabetes, recorded more frequent episodes 
of biochemical hypoglycaemia over a four-week monitoring period and experienced more 
episodes of severe hypoglycaemia in the year preceding the study. Although methods that 
utilise questionnaires are not perfect, the two currently available methods, which are easy 
and quick to administer in the clinical setting, have been externally validated, and 
demonstrate close internal concordance.  
The present study, which has applied a specific method of assessing hypoglycaemia 
awareness in a large outpatient clinic population (using treatments with insulin analogues 
and MDI), has confirmed that the prevalence of IAH has not changed significantly over 
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The DCCT [1] and its follow-up study the EDIC [2] have provided conclusive evidence for 
the need to strive for strict glycaemic control in order to minimise both microvascular and 
macrovascular complications. Strict glycaemic control however usually comes at a price: an 
increased frequency of hypoglycaemia. If hypoglycaemia simply generated some unpleasant 
symptoms to alert the person with diabetes to the fact that the blood glucose concentration 
had fallen and had no effect on cognitive function then strict glycaemic control maybe a 
realistic goal for many with type 1 diabetes. However, cognitive impairment does occur, 
which both prevents self-treatment and can cause dangerous or inappropriate behaviour.  
This therefore remains an important issue for people with type 1 and insulin treated type 2 
diabetes and hopefully the data presented in this thesis has extended our knowledge of the 
effects of hypoglycaemia on cognitive function and the clinical effect of IAH. 
 
10.2 Effects of acute insulin-induced hypoglycaemia on  psychomotor 
function (chapter 5) 
 
The aim of study one was to examine the effects of insulin-induced hypoglycaemia on 
psychomotor function in both healthy volunteers and people with type 1 diabetes. Acute 
hypoglycaemia caused significant impairment of several psychomotor functions in non-
diabetic adults, a lower magnitude of impairment was observed in those with type 1 
diabetes. The mechanism underlying this discrepant effect of hypoglycaemia on 
psychomotor function remains unknown. The groups differed (as would be expected) in 
the magnitude of sympathoadrenal activation mounted in response to the episode of 





concentrations of both adrenaline and noradrenaline, which  potentially could interfere 
with performance on psychomotor testing. Symptoms however are neurally derived from 
activation (via centres in the hypothalamus) of the sympathetic and parasympathetic 
divisions of the autonomic nervous system, with the direct effect of neural stimulation of 
end organs (such as sweat glands) [3]. The blood glucose concentration obtained of 2.5 
mmol/L during hypoglycaemia should have lead to symptom generation in both the 
healthy volunteers and people with diabetes who were selected to have normal awareness 
of hypoglycaemia and a low risk of hypoglycaemia. No significant difference, from the 
study described in chapter 5, in autonomic symptoms was demonstrable between the 
groups (p = 0.274).  
Direct observation of the participants with and without type 1 diabetes, indicated that the 
participants with type 1 diabetes appeared to cope better under the condition of 
hypoglycaemia. They focused more on the tasks and were less distracted than the healthy 
volunteers. This may have arisen through previous exposure to hypoglycaemia. If mild 
hypoglycaemia in the person with type 1 diabetes occurs on average two times per week [4, 
5] some of these episodes will occur while carrying out tasks of everyday living, thus 
potentially conferring a behavioural advantage over a group of hypoglycaemia naïve healthy 
volunteers. 
Cerebral adaptation to cognitive function does occur with certain cognitive tests. As 
described above has the previous exposure to hypoglycaemia in the subjects with type 1 
diabetes lead to cerebral adaptation. Ideally future research would examine this in a group 
of healthy volunteers whereby hypoglycaemia is induced recurrently with cognitive 
function testing and functional brain imaging carried out at each session to ascertain if 
cerebral adaptation does occur. This is problematical for two reasons. One, nowadays it 





volunteers and secondly the exposure from repeated MRI scans would be higher than the 
recommended amount as set out by the International Commission on Non-Ionising 
Radiation Protection. Until this changes and it is possible to do serial brain imaging this 
question may remain unsolved.  
 
10.3  Modelling the Effects of  Hypoglycaemia on a Two-Choice Task in 
Adult Humans 
 
The above study demonstrated that hypoglycaemia affected central processing and not the 
quantity of evidence required to make a decision, or peripheral and motor processes. This 
study is unique in that it is the first to dissect the effect of hypoglycaemia on cognitive 
function this way. Previous research utilising standard psychometric tasks (which provide 
only a total score) only tell us that the domain to which the test relates is affected by 
hypoglycaemia.  For example if we accept that Digit Symbol is a measure of ‘processing 
speed’ and state that, if Digit Symbol performance shows a decrement during 
hypoglycaemia, then hypoglycaemia affects ‘processing speed’. What the current task and 
its model allowed us to do was to dissect in more detail the processing stages that are 
affected. Having now demonstrated that it affects central processing the next logical step 
forward for further studies would be to examine whether ingestion of exogenous 
substances such as amino acids which have been demonstrated to preserve cognitive 
function during hypoglycaemia (as discussed in Chapter 3) do this by preserving central 







10.4 An evaluation of  methods of  assessing impaired awareness of  
hypoglycaemia in Type 1 Diabetes 
 
The main findings of this study was that the participants identified as having IAH by the 
methods of Gold [6] and Clarke [7] had recognised clinical characteristics of this acquired 
syndrome such as older age, a longer duration of diabetes etc, had a higher rate of 
biochemical hypoglycaemia over the 4-week monitoring period and reported a higher 
incidence of severe hypoglycaemia in the year preceding the study compared to those with 
normal awareness. The Pedersen-Bjergaard method [8] was much less discriminating and 
should not be used to identify those with IAH. In both the Gold and Clarke methods a 
score of 1 or 2 signifies normal awareness of hypoglycaemia and a score of 4 or more 
impaired awareness of hypoglycaemia. In this study a few people scored 3 and hence were 
unable to be classified as normal or impaired awareness. Further research is needed to 
refine these methods by studying the group that are currently unclassified to ascertain 
whether their clinical characteristics and frequency of hypoglycaemia can allow them to be 
allocated to one group. Given that both the Gold and Clarke scores are continuous 
variables it would be nice to ascertain if there is a positive relationship between score on 
these methods and incidence of hypoglycaemia. 
 
10.5 Frequency of hypoglycaemia in adults with and without impaired 
awareness of hypoglycaemia 
 
In this study intermittent home glucose monitoring data suggested a 1.6-fold greater risk of 
hypoglycaemia in those with impaired awareness of hypoglycaemia but there was no 
difference in the rate of patient- reported hypoglycaemia and five days of continuous 





hypoglycaemia between NAH and IAH. Finally, the data does not support the use of brief 
duration of CGM to diagnose impaired awareness of hypoglycaemia. It is unknown 
however if a longer period of CGM would be sufficient to differentiate between those with 
and without this clinical syndrome.  The CGM data was collected 5 to 6 years ago and 
significant improvements have been not only in monitor design but the interpretation of 
the data extracted from this. Despite this the Clarke team have reported using the 
Continuous Glucose Error Grid Analysis (CG-EGA) in May 2010 [9], that compared to 
the Yellow Springs blood glucose analyser  (during hypoglycaemic conditions) the 
“clinically accurate”, “benign errors” and “clinical errors” for home blood glucose 
monitoring were 83.5%, 6.4% and 10.1% and for CGM 57.1%, 8.4% and 34.5% 
respectively. Until CGM can accurately identify and not over report the frequency of 
hypoglycaemia there is little to be gained by repeating this study till then. Therefore in 
conclusion at the present time there is no role for CGM in diagnosing individuals with 
IAH.   
 
10.6 Prevalence of Impaired Awareness of Hypoglycaemia in Adults with 
Type 1 Diabetes 
 
The main finding in this study is that despite the recent improvements in insulin 
manufacture, diabetes technology and diabetes education the prevalence of IAH has 
remained relatively static at nearly 20%. The strength of the study was that a large number 
of subjects participated (n=518), representing nearly a third of all people with Type 1 
diabetes who attended clinic at a large University teaching hospital. The group however was 
heterogeneous and if the idea was to ascertain the effect of recent improvements then only 





have been examined.  In reality although they contributed the vast majority of participants 
with 74% on analogues and 82.3% on basal bolus participants on human insulin given 
twice a day were included. Further research should examine only those that have been on 
analogues and intensive insulin regimes since at or shortly after diagnosis to examine these 
effects of the prevalence of IAH which you would expected should be lower due to the 
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